e424b3
The
information in this preliminary prospectus supplement is not
complete and may be changed. A registration statement relating
to these securities has been declared effective by the
Securities and Exchange Commission. We are not using this
preliminary prospectus supplement and the accompanying
prospectus to offer to sell these securities or to solicit
offers to buy these securities in any place where the offer or
sale is not permitted.
|
Filed
Pursuant to Rule 424(b)(3)
Registration
No. 333-157176
SUBJECT TO
COMPLETION DATED FEBRUARY 23, 2011
(To Prospectus dated February 9, 2009)
$
McKesson Corporation
$ % Notes
due 2016
$ % Notes
due 2021
$ % Notes
due 2041
The % notes due 2016, which we
refer to as the 2016 notes, will mature
on ,
2016, the % notes due 2021,
which we refer to as the 2021 notes, will mature
on ,
2021, and the % notes due
2041, which we refer to as the 2041 notes, will
mature
on ,
2041. We refer to the 2016 notes, the 2021 notes and the 2041
notes collectively as the notes. We will pay
interest on the notes
on and
of each year,
beginning ,
2011. We may redeem any series of notes in whole or in part at
any time at the redemption prices set forth under
Description of Notes Optional
Redemption. If a change of control triggering event
occurs, unless we have previously exercised our optional
redemption right, we will be required to offer to repurchase the
notes from the holders for cash. See Description of
Notes Change of Control.
The notes will be unsecured obligations of ours and rank equally
with our existing and future unsecured senior indebtedness. The
notes will be issued only in registered book-entry form and in
denominations of $2,000 and integral multiples of $1,000
thereafter.
Investing in the notes involves
risk. See the section entitled Risk
Factors in our Annual Report on
Form 10-K
for the fiscal year ended March 31, 2010.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Per
|
|
|
|
Per
|
|
|
|
Per
|
|
|
|
|
2016 Note
|
|
Total
|
|
2021 Note
|
|
Total
|
|
2041 Note
|
|
Total
|
|
Public offering price(1)
|
|
|
|
%
|
|
$
|
|
|
|
|
|
%
|
|
$
|
|
|
|
|
|
%
|
|
$
|
|
|
Underwriting discount
|
|
|
|
%
|
|
$
|
|
|
|
|
|
%
|
|
$
|
|
|
|
|
|
%
|
|
$
|
|
|
Proceeds, before expenses, to McKesson(1)
|
|
|
|
%
|
|
$
|
|
|
|
|
|
%
|
|
$
|
|
|
|
|
|
%
|
|
$
|
|
|
|
|
|
(1) |
|
Plus accrued interest from February , 2011, if
settlement occurs after that date. |
Neither the Securities and Exchange Commission nor any state
securities commission has approved or disapproved these
securities or determined if this prospectus supplement or the
accompanying prospectus is truthful or complete. Any
representation to the contrary is a criminal offense.
The notes will be ready for delivery in book-entry form on or
about February , 2011, only through the
facilities of The Depository Trust Company for the accounts
of its participants, which may include Clearstream Banking,
société anonyme, and Euroclear Bank S.A./N.V.,
as operator of the Euroclear System, against payment in New
York, New York.
Joint Book-Running Managers
|
|
BofA
Merrill Lynch |
J.P. Morgan |
February , 2011
TABLE OF
CONTENTS
|
|
|
|
|
|
|
|
|
S-1
|
|
|
|
|
S-1
|
|
|
|
|
S-2
|
|
|
|
|
S-5
|
|
|
|
|
S-6
|
|
|
|
|
S-7
|
|
|
|
|
S-8
|
|
|
|
|
S-16
|
|
|
|
|
S-18
|
|
|
|
|
S-21
|
|
|
|
|
S-21
|
|
|
|
|
S-21
|
|
|
|
|
|
|
1
|
|
|
|
|
1
|
|
|
|
|
2
|
|
|
|
|
2
|
|
|
|
|
2
|
|
|
|
|
3
|
|
|
|
|
3
|
|
|
|
|
7
|
|
|
|
|
10
|
|
|
|
|
18
|
|
|
|
|
20
|
|
|
|
|
20
|
|
|
|
|
22
|
|
|
|
|
22
|
|
ABOUT
THIS PROSPECTUS SUPPLEMENT
This document is in two parts. The first is this prospectus
supplement, which describes the specific terms of this offering,
the notes and matters relating to us and our financial
performance and condition. The second part, the accompanying
prospectus, provides a more general description of the terms and
conditions of the various securities we may offer under our
registration statement, some of which does not apply to this
offering. If the description of this offering and the notes
varies between this prospectus supplement and the accompanying
prospectus, you should rely on the information in this
prospectus supplement.
In various places in this prospectus supplement and the
accompanying prospectus, we refer you to sections of other
documents for additional information by indicating the caption
heading of the other sections. All cross-references in this
prospectus supplement are to captions contained in this
prospectus supplement and not in the accompanying prospectus,
unless otherwise indicated.
FORWARD-LOOKING
STATEMENTS
This prospectus supplement and the documents incorporated by
reference herein include forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as
amended (the Securities Act), and Section 21E
of the Securities Exchange Act of 1934, as amended (the
Exchange Act). Some of these statements can be
identified by the use of forward-looking words such as
believes, expects,
anticipates, may, will,
should, seeks,
approximately, intends,
plans or estimates, or the negative of
these words, or other comparable terminology. Forward-looking
statements involve risks and uncertainties that could cause
actual results to differ materially from those projected,
anticipated or implied. Although it is not possible to predict
or identify all such risks and uncertainties, they may include,
but are not limited to, the factors discussed under Risk
Factors in our Annual Report on
Form 10-K
and in other information contained in our publicly available SEC
filings and press releases. You should not consider this list to
be a complete statement of all potential risks and
uncertainties. You are cautioned not to place undue reliance on
any such forward-looking statements, which speak only as of the
date such statements were first made. Except to the extent
required by federal securities laws, we undertake no obligation
to publicly release the result of any revisions to these
forward-looking statements to reflect events or circumstances
after the date hereof or to reflect the occurrence of
unanticipated events.
You should carefully read this prospectus supplement, the
accompanying prospectus and the documents incorporated by
reference in their entirety. They contain information that you
should consider when making your investment decision.
We have not, and the underwriters have not, authorized any other
person, including any dealer, salesperson or other individual,
to provide you with any information or to make any
representations other than those contained or incorporated by
reference in this prospectus supplement and the accompanying
prospectus. We take no responsibility for, and can provide no
assurance as to the reliability of, any other information that
others may give you. We are not, and the underwriters are not,
making an offer to sell these securities in any jurisdiction
where the offer or sale is not permitted. You should assume that
the information in this prospectus supplement, the accompanying
prospectus and the documents incorporated by reference is
accurate only as of their respective dates. We undertake no
obligation to publicly update or revise any forward-looking
statements, whether as a result of new information, future
events or otherwise. Our business, financial condition, results
of operations and prospects may have changed since those dates.
This prospectus supplement and the accompanying prospectus do
not constitute an offer to sell or the solicitation of an offer
to buy any securities other than the securities to which they
relate or an offer to sell or the solicitation of an offer to
buy such securities in any circumstances in which such offer or
solicitation is unlawful. Neither the delivery of this
prospectus supplement and the accompanying prospectus nor any
sale made hereunder or thereunder shall, under any
circumstances, create any implication that there has been no
change in our affairs since the date hereof or that the
information contained herein or therein is correct as of any
time subsequent to the date hereof.
S-1
SUMMARY
This summary highlights information contained elsewhere in
this prospectus supplement and the accompanying prospectus. It
does not contain all of the information that you should consider
before making an investment decision. We urge you to read
carefully the entire prospectus supplement, the accompanying
prospectus and the documents incorporated by reference in this
prospectus supplement and the accompanying prospectus, including
the historical financial statements and notes to those financial
statements included or incorporated by reference in this
prospectus supplement and the accompanying prospectus. Please
read Risk Factors in our Annual Report on
Form 10-K
for the year ended March 31, 2010 for more information
about important risks that you should consider before investing
in the notes. Except as otherwise indicated, all references in
this prospectus supplement to McKesson, the
company, we, our and
us refer to McKesson Corporation and its
consolidated subsidiaries.
McKesson
Corporation
McKesson Corporation (NYSE: MCK) is a healthcare services and
information technology company providing supply, information and
care management products and services designed to reduce costs
and improve quality across the healthcare industry.
We conduct our business through two
segments. The McKesson Distribution Solutions
segment distributes ethical and proprietary drugs,
medical-surgical supplies and equipment, and health and beauty
care products throughout North America. This segment also
provides specialty pharmaceutical solutions for biotech and
pharmaceutical manufacturers, sells financial, operational and
clinical solutions for pharmacies (retail, hospital, long-term
care) and provides consulting, outsourcing and other services.
This segment includes a 49% interest in Nadro, S.A. de C.V., one
of the leading pharmaceutical distributors in Mexico, and a 39%
interest in Parata Systems, LLC, which sells automated pharmacy
and supply management systems and services to retail and
institutional outpatient pharmacies. The McKesson Technology
Solutions segment delivers enterprise-wide clinical, patient
care, financial, supply chain, strategic management software
solutions, pharmacy automation for hospitals, as well as
connectivity, outsourcing and other services, including remote
hosting and managed services, to healthcare organizations. This
segment also includes our Payor group of businesses, which
includes our
InterQual®
claims payment solutions, medical management software businesses
and our care management programs. The segments customers
include hospitals, physicians, homecare providers, retail
pharmacies and payors from North America, the United Kingdom,
Ireland, other European countries, Asia Pacific and Israel.
Our principal executive offices are located at McKesson Plaza,
One Post Street, San Francisco, California 94104. Our
telephone number is
(415) 983-8300.
S-2
The
Offering
|
|
|
Issuer |
|
McKesson Corporation |
|
Securities Offered |
|
$ aggregate principal amount of
notes, consisting of: |
|
|
|
$
aggregate principal amount
of % notes due 2016.
|
|
|
|
$
aggregate principal amount
of % notes due 2021.
|
|
|
|
$
aggregate principal amount
of % notes due 2041.
|
|
Maturity Date |
|
2016
notes ,
2016. |
|
|
|
2021
notes ,
2021. |
|
|
|
2041
notes ,
2041. |
|
Interest Rate |
|
2016 notes % per year. |
|
|
|
2021 notes % per year. |
|
|
|
2041 notes % per year. |
|
Interest Payment Dates |
|
Interest will be paid
on
and
of each year, beginning
on ,
2011. Interest on the notes will accrue
from ,
2011. |
|
Use of Proceeds |
|
We estimate that we will receive approximately
$ million from the sale of
the notes, after deducting underwriting discounts and estimated
offering expenses. We will use the net proceeds from this
offering for general corporate purposes, including the repayment
of borrowings under the Senior Bridge Term Loan Agreement (the
Bridge Loan) among us, Bank of America, N.A., as
administrative agent, and the lenders party thereto. See
Use of Proceeds. |
|
Conflicts of Interest |
|
Certain of the underwriters or their affiliates are agents
and/or lenders under the Bridge Loan. As described in Use
of Proceeds, a portion of the net proceeds from this
offering may be used to repay outstanding borrowings under the
Bridge Loan. As affiliates of J.P. Morgan Securities LLC
and Merrill Lynch, Pierce, Fenner & Smith Incorporated
may each receive more than 5% of the proceeds of this offering,
not including underwriting compensation, J.P. Morgan
Securities LLC and Merrill Lynch, Pierce, Fenner &
Smith Incorporated each may have a conflict of
interest as defined in Rule 5121 adopted by the
Financial Industry Regulatory Authority, Inc., or FINRA.
Consequently, this offering will be conducted in accordance with
Rule 5121. No underwriter having a conflict of interest
will confirm sales to accounts over which discretionary
authority is exercised without the prior written consent of the
accountholder. In accordance with Rule 5121, a
qualified independent underwriter is not required
because the notes offered are investment grade rated, as that
term is defined in Rule 5121. See Use of
Proceeds and Underwriting Conflicts of
Interest. |
S-3
|
|
|
Optional Redemption |
|
We may redeem the notes of each series for cash in whole, at any
time, or in part, from time to time, prior to maturity, at
redemption prices that include accrued and unpaid interest and a
make-whole premium. However, no make-whole premium will be paid
for redemptions of the 2021 notes during the three-month period
prior to their maturity, or for redemptions of the 2041 notes
during the six-month period prior to their maturity. See
Description of Notes Optional Redemption. |
|
Change of Control |
|
Upon the occurrence of both (1) a change of control of us
and (2) a downgrade of a series of notes below an
investment grade rating by each of Fitch Inc., Moodys
Investors Service, Inc. and Standard & Poors
Ratings Services within a specified period, unless we have
previously exercised our optional redemption right with respect
to that series of notes in whole, we will be required to offer
to repurchase the notes of that series at a price equal to 101%
of the then outstanding principal amount of such series, plus
accrued and unpaid interest to, but not including, the date of
repurchase. See Description of Notes Change of
Control. |
|
Other Covenants |
|
We will issue the notes under an indenture with Wells Fargo
Bank, National Association. The indenture includes certain
covenants, including limitations on our ability to: |
|
|
|
create liens on our assets;
|
|
|
|
enter into sale and lease-backs with
respect to our properties; and
|
|
|
|
merge or consolidate with another entity.
|
|
|
|
These covenants are subject to a number of important exceptions,
limitations and qualifications that are described under
Description of Notes Certain Covenants
and in our indenture. |
|
Ranking |
|
The notes will be our unsecured senior obligations and will rank
equally with all our existing and future unsecured and
unsubordinated indebtedness from time to time outstanding. |
|
|
|
The indenture does not limit the amount of debt we may incur. |
|
Additional Issues |
|
We may create and issue additional notes with the same terms
(except for the issue date, the public offering price and, under
certain circumstances, the first interest payment date) as one
or more series of the notes so that such additional notes shall
be consolidated and form a single series with the notes of the
corresponding series. |
S-4
USE OF
PROCEEDS
We estimate that the net proceeds from this offering will be
approximately $ million,
after deducting underwriting discounts and estimated offering
expenses. We plan to use the net proceeds from the sale of the
notes for general corporate purposes, including the repayment of
borrowings outstanding under the Bridge Loan. We recently
acquired U.S. Oncology Holdings, Inc.
(U.S. Oncology). On January 31, 2011, we
borrowed $1.0 billion under the Bridge Loan to fund the
redemption of certain indebtedness of U.S. Oncology and its
wholly-owned subsidiary U.S. Oncology, Inc. Borrowings
under the Bridge Loan must be repaid in full no later than
December 30, 2011, or, in full or in part, upon certain
events occurring prior to such time, including specified debt
issuances such as this offering. The Bridge Loan bears interest
based on the London Interbank Offered Rate plus a margin based
on our credit ratings and the amount of time any borrowings
under the Bridge Loan remain outstanding. As of
February 22, 2011, our borrowing under the Bridge Loan
accrued interest at the rate of 1.76% per year.
Certain affiliates of the underwriters are lenders
and/or
agents under the Bridge Loan. Therefore, affiliates of the
underwriters will receive a portion of the net proceeds from
this offering used to repay borrowings under the Bridge Loan.
See Underwriting Conflicts of Interest
for more information.
S-5
CAPITALIZATION
The following table sets forth our cash position and
capitalization as of December 31, 2010:
|
|
|
|
|
on an actual basis;
|
|
|
|
on an adjusted basis to give effect to the incurrence of
indebtedness under the Bridge Loan and the redemption of certain
U.S. Oncology and U.S. Oncology, Inc. debt acquired in
connection with the U.S. Oncology acquisition; and
|
|
|
|
on an adjusted basis to give effect to the incurrence of
indebtedness under our Bridge Loan, the redemption of certain
U.S. Oncology and U.S. Oncology, Inc. debt acquired in
connection with the U.S. Oncology acquisition, this
offering and the application of the net proceeds from the sale
of the notes. See Use of Proceeds.
|
You should read this table in conjunction with Managements
Discussion and Analysis of Financial Condition and Results of
Operations and our historical financial statements and notes to
those financial statements that are incorporated by reference in
this prospectus supplement and the accompanying prospectus.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
As of December 31, 2010
|
|
|
|
|
|
|
Adjusted
|
|
|
Adjusted for Bridge
|
|
|
|
|
|
|
for Bridge Loan and
|
|
|
Loan, U.S. Oncology
|
|
|
|
|
|
|
U.S. Oncology Debt
|
|
|
Debt Redemption and
|
|
|
|
Actual
|
|
|
Redemption
|
|
|
this Offering
|
|
|
|
|
|
|
(Unaudited)
|
|
|
|
|
|
|
|
|
|
(In millions)
|
|
|
|
|
|
Cash and cash equivalents
|
|
$
|
3,213
|
|
|
$
|
2,473
|
|
|
$
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Long-term debt (including current portion):
|
|
|
|
|
|
|
|
|
|
|
|
|
7.75% Notes due February 2012
|
|
$
|
400
|
|
|
$
|
400
|
|
|
$
|
400
|
|
5.25% Notes due March 2013
|
|
|
499
|
|
|
|
499
|
|
|
|
499
|
|
6.50% Notes due February 2014
|
|
|
350
|
|
|
|
350
|
|
|
|
350
|
|
5.70% Notes due March 2017
|
|
|
499
|
|
|
|
499
|
|
|
|
499
|
|
7.50% Notes due February 2019
|
|
|
349
|
|
|
|
349
|
|
|
|
349
|
|
7.65% Debentures due March 2027
|
|
|
175
|
|
|
|
175
|
|
|
|
175
|
|
U.S. Oncology debt(1)
|
|
|
1,740
|
|
|
|
|
|
|
|
|
|
Bridge Loan
|
|
|
|
|
|
|
1,000
|
|
|
|
|
|
Other debt
|
|
|
50
|
|
|
|
50
|
|
|
|
50
|
|
% Notes
due 2016
|
|
|
|
|
|
|
|
|
|
|
|
|
% Notes
due 2021
|
|
|
|
|
|
|
|
|
|
|
|
|
% Notes
due 2041
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total long-term debt (including current portion)
|
|
$
|
4,062
|
|
|
$
|
3,322
|
|
|
$
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stockholders equity:
|
|
|
|
|
|
|
|
|
|
|
|
|
Preferred stock, $0.01 par value, 100 shares
authorized, no shares issued or outstanding
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
Common stock $0.01 par value, 800 shares authorized;
365 shares issued
|
|
|
4
|
|
|
|
4
|
|
|
|
4
|
|
Additional paid-in capital
|
|
|
5,153
|
|
|
|
5,153
|
|
|
|
5,153
|
|
Retained earnings
|
|
|
7,876
|
|
|
|
7,876
|
|
|
|
7,876
|
|
Accumulated other comprehensive income
|
|
|
51
|
|
|
|
51
|
|
|
|
51
|
|
Other
|
|
|
2
|
|
|
|
2
|
|
|
|
2
|
|
Treasury shares, at cost 111 shares
|
|
|
(6,006
|
)
|
|
|
(6,006
|
)
|
|
|
(6,006
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total stockholders equity
|
|
$
|
7,080
|
|
|
$
|
7,080
|
|
|
$
|
7,080
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total capitalization
|
|
$
|
11,142
|
|
|
$
|
10,402
|
|
|
$
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) |
|
Represents the aggregate fair value of the principal amount and
associated redemption premiums, as applicable, of Senior
Unsecured Floating Rate Toggle Notes due 2012 of
U.S. Oncology, 9.125% Senior Secured Notes due 2017 of
U.S. Oncology, Inc., and 10.75% Senior Subordinated
Notes due 2014 of U.S. Oncology, Inc. |
S-6
RATIO OF
EARNINGS TO FIXED CHARGES
The table below reflects our ratio of earnings to fixed charges
for the following periods: (1) the nine months ended
December 31, 2010, and (2) each of the five years in
the period ended March 31, 2010.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the Nine
|
|
|
|
|
|
|
|
|
|
|
|
|
Months Ended
|
|
|
|
|
|
|
|
|
|
|
|
|
December 31,
|
|
For the Year Ended March 31,
|
|
|
2010
|
|
2010
|
|
2009
|
|
2008
|
|
2007
|
|
2006
|
|
Ratio of earnings to fixed charges(1)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Actual
|
|
|
7.1
|
|
|
|
8.8
|
|
|
|
6.5
|
|
|
|
8.3
|
|
|
|
10.1
|
|
|
|
9.7
|
|
|
|
|
(1) |
|
The ratio of earnings to fixed charges is computed by dividing
fixed charges (interest cost, both expensed and capitalized,
including amortization of debt discounts and deferred loan
costs, and the interest component of rental expense) into
earnings available for fixed charges (income from continuing
operations before income taxes plus fixed charges, minus equity
in net income of and dividends from equity investees and
interest capitalized). |
S-7
DESCRIPTION
OF NOTES
This description of the notes being offered hereby supplements
and, to the extent it is inconsistent, replaces, the description
of the general provisions of the notes and the indenture in the
accompanying prospectus. The notes will be Senior Debt
Securities, as that term is used in the accompanying
prospectus.
General
The 2016 notes, the 2021 notes and the 2041 notes will each be
issued as a separate series of debt securities under the
indenture dated as of March 5, 2007 (the Base
Indenture). Certain terms of the notes are contained in a
supplemental indenture (the Supplemental Indenture,
and together with the Base Indenture, the indenture
between us and Wells Fargo Bank, National Association, as
trustee). You may request a copy of the indenture and the form
of note from the trustee.
We will issue the notes in fully registered book-entry form
without coupons and in denominations of $2,000 and integral
multiples of $1,000 thereafter. We do not intend to apply for
the listing of the notes on a national securities exchange or
for quotation of the notes on any automated dealer quotation
system.
The following statements relating to the notes and the indenture
are summaries of certain provisions thereof and are subject to
the detailed provisions of the indenture, to which reference is
hereby made for a complete statement of such provisions. Certain
provisions of the indenture are summarized in the accompanying
prospectus. We encourage you to read the summaries of the notes
and the indenture in both this prospectus supplement and the
accompanying prospectus, as well as the form of notes and the
indenture.
The notes will be our senior unsecured obligations. The cover
page of this prospectus supplement sets forth the respective
maturity dates, aggregate principal amounts and interest rates
of the notes of each series. The notes will bear interest from
the date of issuance, payable semi-annually on
each
and ,
beginning ,
2011, to the persons in whose names the notes are registered at
the close of business on
the
immediately preceding
each
and
the
immediately preceding
each .
Interest will be computed on the basis of a
360-day year
composed of twelve
30-day
months. Payments of principal, premium if any, and interest to
owners of book-entry interests (as described below) are expected
to be made in accordance with the procedures of The Depository
Trust Company (DTC) and its participants in
effect from time to time.
We may, without the consent of the holders of the notes, create
and issue additional notes with the same terms (except for the
issue date, the public offering price and, under certain
circumstances, the first interest payment date) as one or more
series of the notes. The additional notes will form a single
series with the outstanding notes of the corresponding series.
No additional notes may be issued if an event of default has
occurred and is continuing with respect to such series of notes.
Optional
Redemption
We may redeem:
(a) the 2016 notes,
(b) the 2021 notes prior to three months before their
maturity date, or
(c) the 2041 notes prior to six months before their
maturity date
in whole, at any time, or in part, from time to time, at our
option, for cash, at a redemption price equal to the greater of:
(1) 100% of the principal amount of the notes to be
redeemed; or
(2) an amount determined by the Quotation Agent equal to
the sum of the present values of the remaining scheduled
payments of principal and interest thereon (not including any
portion of such payments of interest accrued to the date of
redemption), discounted to the date of redemption on a
semi-annual basis (assuming a
360-day year
consisting of twelve
30-day
months) at the Treasury Rate (as
S-8
defined below),
plus
basis points with respect to the 2016
notes, basis
points with respect to the 2021 notes
and
basis points with respect to the 2041 notes,
plus, in each case, accrued and unpaid interest thereon to, but
not including, the date of redemption.
On or after the date that is three months prior to the maturity
for the 2021 notes, or six months prior to the maturity for the
2041 notes, we may redeem the 2021 notes or the 2041 notes in
whole, at any time, or in part, from time to time, at our
option, for cash, at a redemption price equal to 100% of the
principal amount of such notes, plus accrued and unpaid interest
to, but not including, the redemption date.
The principal amount of any note remaining outstanding after a
redemption in part shall be $2,000 or a higher integral multiple
of $1,000. Notwithstanding the foregoing, installments of
interest on notes that are due and payable on interest payment
dates falling on or prior to a redemption date will be payable
on the interest payment date to the registered holders as of the
close of business on the relevant record date.
Comparable Treasury Issue means the United States
Treasury security selected by the Quotation Agent as having a
maturity comparable to the remaining term of the notes of the
applicable series to be redeemed that would be utilized, at the
time of selection and in accordance with customary financial
practice, in pricing new issues of corporate debt securities of
comparable maturity to the remaining term of such series of
notes.
Comparable Treasury Price means, with respect to any
redemption date, (1) the average of four Reference Treasury
Dealer Quotations for such redemption date, after excluding the
highest and lowest of such Reference Treasury Dealer Quotations,
or (2) if the trustee obtains fewer than four such
Reference Treasury Dealer Quotations, the average of all such
quotations.
Quotation Agent means the Reference Treasury Dealer
appointed by us.
Reference Treasury Dealer means (1) J.P. Morgan
Securities LLC and Merrill Lynch, Pierce, Fenner &
Smith Incorporated and their respective successors; provided,
however, that if any of the foregoing shall cease to be a
primary U.S. Government securities dealer in New York City
(a Primary Treasury Dealer), we will substitute
therefor another Primary Treasury Dealer, and (2) any other
Primary Treasury Dealers selected by us.
Reference Treasury Dealer Quotations means, with
respect to each Reference Treasury Dealer and any redemption
date, the average, as determined by the trustee, of the bid and
asked prices for the Comparable Treasury Issue (expressed in
each case as a percentage of its principal amount) quoted in
writing to the trustee by such Reference Treasury Dealer at
5:00 p.m., New York City time, on the third business day
preceding such redemption date.
Treasury Rate means, with respect to any redemption
date, the rate per annum equal to the semi-annual equivalent
yield to maturity of the Comparable Treasury Issue, assuming a
price for the Comparable Treasury Issue (expressed as a
percentage of its principal amount) equal to the Comparable
Treasury Price on such redemption date.
Notice of any redemption will be mailed at least 30 days
but not more than 60 days before the redemption date to
each registered holder of the notes to be redeemed. Unless we
default in payment of the redemption price, on and after the
redemption date, interest will cease to accrue on the notes or
portions thereof called for redemption. If less than all of the
notes of a series are to be redeemed, the notes of such series
to be redeemed will be selected by the trustee by a method the
trustee deems to be fair and appropriate.
Change of
Control
If a Change of Control Triggering Event (as defined below)
occurs, unless we have previously exercised our right to redeem
the notes of a series in whole as described above, holders of
notes of that series will have the right to require us to
repurchase all or any part (in integral multiples of $1,000
original principal amount) of their notes of that series
pursuant to the offer described below (the Change of
Control Offer) on the terms set forth in such notes;
provided that the principal amount of any note remaining
outstanding after a repurchase in part shall be $2,000 or a
higher integral multiple of $1,000. In the Change of Control
Offer, we will be required to offer payment in cash equal to
101% of the then outstanding aggregate principal amount of
S-9
notes of that series repurchased plus accrued and unpaid
interest, if any, on the notes repurchased, to, but not
including, the date of repurchase (the Change of Control
Payment). Within 30 days following any Change of
Control Triggering Event, we will be required to mail a notice
to holders of notes of the series subject to the Change of
Control Triggering Event describing the transaction or
transactions that constitute the Change of Control Triggering
Event and offering to repurchase the notes of that series on the
date specified in the notice, which date will be no earlier than
30 days and no later than 60 days from the date such
notice is mailed (the Change of Control Payment
Date), pursuant to the procedures required by such notes
and described in such notice. We must comply with the
requirements of
Rule 14e-1
under the Exchange Act and any other securities laws and
regulations thereunder to the extent those laws and regulations
are applicable in connection with the repurchase of the notes as
a result of a Change of Control Triggering Event. To the extent
that the provisions of any securities laws or regulations
conflict with the Change of Control provisions of the notes, we
will be required to comply with the applicable securities laws
and regulations and will not be deemed to have breached our
obligations under the Change of Control provisions of the notes
by virtue of such conflicts.
On the Change of Control Payment Date, we will be required, to
the extent lawful, to:
|
|
|
|
|
accept for payment all notes or portions thereof properly
tendered pursuant to the Change of Control Offer;
|
|
|
|
|
|
deposit with the paying agent, no later than 11:00 a.m.,
New York City time, an amount equal to the Change of Control
Payment in respect of all notes or portions of notes properly
tendered; and
|
|
|
|
deliver or cause to be delivered to the trustee the notes
properly accepted together with an officers certificate
stating the aggregate principal amount of notes or portions of
notes being repurchased.
|
The paying agent will promptly mail to each holder of notes
properly tendered the repurchase price for such notes, and the
trustee will promptly authenticate and mail (or cause to be
transferred by book-entry) to each holder a new note equal in
principal amount to any unrepurchased portion of any notes
surrendered; provided, that each new note will be in a principal
amount of $2,000 or an integral multiple of $1,000 thereafter.
The definition of Change of Control includes a phrase relating
to the direct or indirect sale, lease, transfer, conveyance or
other disposition of all or substantially all of the
properties or assets of ours and our subsidiaries taken as a
whole. Although there is a limited body of case law interpreting
the phrase substantially all, there is no precise
established definition of the phrase under applicable law.
Accordingly, the ability of a holder of notes to require us to
repurchase its notes as a result of a sale, lease, transfer,
conveyance or other disposition of less than all of the assets
of ours and our subsidiaries taken as a whole to another Person
(as defined in the indenture) or group may be uncertain.
We will not be required to make a Change of Control Offer upon
the occurrence of a Change of Control Triggering Event if a
third party makes such an offer in the manner, at the times and
otherwise in compliance with the requirements for a Change of
Control Offer made by us and the third party repurchases all
notes properly tendered and not withdrawn under its offer. In
addition, we will not repurchase any notes if there has occurred
and is continuing on the Change of Control Payment Date an event
of default under the indenture, other than a default in the
payment of the Change of Control Payment upon a Change of
Control Triggering Event.
The change of control feature of the notes may in certain
circumstances make more difficult or discourage a sale or
takeover of us and, thus, the removal of incumbent management.
We could, in the future, enter into certain transactions,
including acquisitions, refinancings or other recapitalizations,
that would not constitute a Change of Control under the notes,
but that could increase the amount of our indebtedness
outstanding at such time or otherwise affect our capital
structure or credit ratings on the notes.
For purposes of the foregoing discussion of a repurchase at the
option of holders, the following definitions are applicable:
Below Investment Grade Rating Event means with
respect to each series of notes, the notes of that series are
rated below an Investment Grade Rating by each of the Rating
Agencies (as defined below) on any date from the date of the
public notice of an arrangement that could result in a Change of
Control until the end of the
60-day
period following public notice of the occurrence of the Change
of Control
S-10
(which
60-day
period shall be extended so long as the rating of the notes is
under publicly announced consideration for possible downgrade by
any of the Rating Agencies).
Change of Control means the occurrence of any of the
following: (1) the direct or indirect sale, transfer,
conveyance or other disposition (other than by way of merger or
consolidation), in one or a series of related transactions, of
all or substantially all of the properties or assets of ours and
our subsidiaries taken as a whole to any person (as
that term is used in Section 13(d)(3) of the Exchange Act)
other than us or one of our subsidiaries; (2) the
consummation of any transaction (including, without limitation,
any merger or consolidation) the result of which is that any
person (as that term is used in
Section 13(d)(3) of the Exchange Act) becomes the
beneficial owner, directly or indirectly, of more than 50% of
the then outstanding number of shares of our voting stock; or
(3) the first day on which a majority of the members of our
Board of Directors are not Continuing Directors. Notwithstanding
the foregoing, a transaction will not be deemed to result in a
Change of Control if (a) we become a wholly-owned
subsidiary of a holding company and (b) the holders of the
voting stock of such holding company immediately following that
transaction are substantially the same as the holders of
McKessons voting stock immediately prior to that
transaction.
Change of Control Triggering Event means the
occurrence of both a Change of Control and a Below Investment
Grade Rating Event.
Continuing Directors means, as of any date of
determination, any member of our Board of Directors who
(1) was a member of such Board of Directors on the date of
the issuance of the notes; or (2) was nominated for
election or elected to such Board of Directors with the approval
of a majority of the Continuing Directors who were members of
such Board of Directors at the time of such nomination or
election (either by a specific vote or by approval of our proxy
statement in which such member was named as a nominee for
election as a director, without objection to such nomination).
Fitch means Fitch Inc., a subsidiary of Fimalac, S.A.
Investment Grade Rating means a rating equal to or
higher than BBB- (or the equivalent) by Fitch, Baa3 (or the
equivalent) by Moodys and BBB- (or the equivalent) by
S&P.
Moodys means Moodys Investors Service,
Inc.
Rating Agencies means (1) each of Fitch,
Moodys and S&P; and (2) if any of Fitch,
Moodys or S&P ceases to rate the notes or fails to
make a rating of the notes publicly available for reasons
outside of our control, a nationally recognized
statistical rating organization within the meaning of
Rule 15c3-1(c)(2)(vi)(F)
under the Exchange Act, selected by us as a replacement agency
for Fitch, Moodys or S&P, or all of them, as the case
may be.
S&P means Standard & Poors
Ratings Services, a division of The McGraw-Hill Companies, Inc.
Certain
Covenants
Definitions
The term Attributable Debt shall mean in connection
with a sale and lease-back transaction the lesser of
(a) the fair value of the assets subject to such
transaction, as determined by our Board of Directors, or
(b) the present value of the obligations of the lessee for
net rental payments during the term of any lease discounted at
the rate of interest set forth or implicit in the terms of such
lease or, if not practicable to determine such rate, the
weighted average interest rate per annum borne by the debt
securities of each series outstanding pursuant to the indenture
and subject to limitations on sale and lease-back transaction
covenants, compounded semi-annually in either case as determined
by our principal accounting or financial officer.
The term Consolidated Subsidiary shall mean any
Subsidiary (as defined in the indenture) substantially all the
property of which is located, and substantially all the
operations of which are conducted, in the United
S-11
States of America whose financial statements are consolidated
with our financial statements in accordance with accounting
principles generally accepted in the United States of America.
The term Exempted Debt shall mean the sum of the
following as of the date of determination: (1) Indebtedness
of ours and our Consolidated Subsidiaries incurred after the
date of issuance of the notes and secured by liens not permitted
by the limitation on liens provisions, and (2) Attributable
Debt of ours and our Consolidated Subsidiaries in respect of
every sale and lease-back transaction entered into after the
date of the issuance of the notes, other than leases permitted
by the limitation on sale and lease-back provisions.
The term Indebtedness shall mean all items
classified as indebtedness on our most recently available
consolidated balance sheet, in accordance with accounting
principles generally accepted in the United States of America.
The term Qualified Receivables Transaction shall
mean any transaction or series of transactions entered into by
us or any of our Subsidiaries pursuant to which we or any of our
Subsidiaries sells, conveys or otherwise transfers to (1) a
Receivables Subsidiary (in the case of a transfer by us or any
of our Subsidiaries) or (2) any other person (in the case
of a transfer by a Receivables Subsidiary), or grants a security
interest in, any accounts receivable (whether now existing or
arising in the future) or inventory of us or any of our
Subsidiaries, and any assets related thereto including, without
limitation, all collateral securing such accounts receivable,
all contracts and all guarantees or other obligations in respect
of such accounts receivable or inventory, proceeds of such
accounts receivable and other assets which are customarily
transferred or in respect of which security interests are
customarily granted in connection with asset securitization
transactions involving accounts receivable or inventory.
The term Receivables Subsidiary shall mean a
Subsidiary of ours which engages in no activities other than in
connection with the financing of accounts receivable or
inventory (a) no portion of the Indebtedness or any other
obligations (contingent or otherwise) of which (1) is
guaranteed by us or any Subsidiary of ours (excluding guarantees
of obligations (other than the principal of, and interest on,
Indebtedness) pursuant to representations, warranties, covenants
and indemnities entered into in the ordinary course of business
in connection with a Qualified Receivables Transaction),
(2) is recourse or obligates us or any Subsidiary of ours
in any way other than pursuant to representations, warranties,
covenants and indemnities entered into in the ordinary course of
business in connection with a Qualified Receivables Transaction
or (3) subjects any property or asset of ours or any
Subsidiary of ours (other than accounts receivable or inventory
and related assets as provided in the definition of
Qualified Receivables Transaction), directly or
indirectly, contingently or otherwise, to the satisfaction
thereof, other than pursuant to representations, warranties,
covenants and indemnities entered into in the ordinary course of
business in connection with a Qualified Receivables Transaction,
(b) with which neither we nor any Subsidiary of ours has
any material contract, agreement, arrangement or understanding
other than on terms customary for securitization of receivables
or inventory and (c) with which neither we nor any
Subsidiary of ours has any obligations to maintain or preserve
such Subsidiarys financial condition or cause such
Subsidiary to achieve certain levels of operating results.
Limitation
on Liens
We covenant that, so long as any of the notes remain
outstanding, we will not, and will not permit any Consolidated
Subsidiary, to create or assume any Indebtedness for money
borrowed which is secured by a mortgage, pledge, security
interest or lien (liens) of or upon any assets,
whether now owned or hereafter acquired, of ours or any such
Consolidated Subsidiary without equally and ratably securing the
notes by a lien ranking equally to and ratably with (or, at our
option, senior to) such secured Indebtedness, except that the
foregoing restriction shall not apply to:
|
|
|
|
|
liens on assets of any corporation existing at the time such
corporation becomes a Consolidated Subsidiary;
|
|
|
|
liens on assets existing at the time of acquisition thereof, or
to secure the payment of the purchase price of such assets, or
to secure indebtedness incurred or guaranteed by us or a
Consolidated Subsidiary for the purpose of financing the
purchase price of such assets or improvements or construction
thereon,
|
S-12
|
|
|
|
|
which indebtedness is incurred or guaranteed prior to, at the
time of or within 360 days after such acquisition, or in
the case of real property, completion of such improvement or
construction or commencement of full operation of such property,
whichever is later;
|
|
|
|
|
|
liens securing indebtedness owed by any Consolidated Subsidiary
to us or another wholly owned Subsidiary;
|
|
|
|
liens on any assets of a corporation existing at the time such
corporation is merged into or consolidated with us or a
Subsidiary or at the time of a purchase, lease or other
acquisition of the assets of the corporation or firm as an
entirety or substantially as an entirety by us or a Subsidiary;
|
|
|
|
liens on any assets of ours or a Consolidated Subsidiary in
favor of the United States of America or any state thereof, or
in favor of any other country, or political subdivision thereof,
to secure certain payments pursuant to any contract or statute
or to secure any indebtedness incurred or guaranteed for the
purpose of financing all or any part of the purchase price, or,
in the case of real property, the cost of construction, of the
assets subject to such liens, including, but not limited to,
liens incurred in connection with pollution control, industrial
revenue or similar financing;
|
|
|
|
any extension, renewal or replacement, or successive extensions,
renewals or replacements, in whole or in part, of any lien
referred to in the foregoing;
|
|
|
|
certain statutory liens or other similar liens arising in the
ordinary course of our or a Consolidated Subsidiarys
business, or certain liens arising out of government contracts;
|
|
|
|
certain pledges, deposits or liens made or arising under the
workers compensation or similar legislation or in certain
other circumstances;
|
|
|
|
certain liens in connection with legal proceedings, including
certain liens arising out of judgments or awards;
|
|
|
|
liens for certain taxes or assessments, landlords liens
and liens and charges incidental to the conduct of the business
or the ownership of our assets or those of a Consolidated
Subsidiary, which were not incurred in connection with the
borrowing of money and which do not, in our opinion, materially
impair the use of such assets in the operation of our business
or that of such Consolidated Subsidiary or the value of such
assets for the purposes thereof;
|
|
|
|
liens relating to accounts receivable of ours or any of our
Subsidiaries which have been sold, assigned or otherwise
transferred to another Person in a transaction classified as a
sale of accounts receivable in accordance with accounting
principles generally accepted in the United States of America,
to the extent the sale by us or the applicable Subsidiary is
deemed to give rise to a lien in favor of the purchaser thereof
in such accounts receivable or the proceeds thereof; or
|
|
|
|
liens on any assets of ours or any of our Subsidiaries
(including Receivables Subsidiaries) incurred in connection with
a Qualified Receivables Transaction.
|
Notwithstanding the above, we or any of our Consolidated
Subsidiaries may, without securing the notes, create or assume
any Indebtedness which is secured by a lien which would
otherwise be subject to the foregoing restrictions; provided
that after giving effect thereto the Exempted Debt then
outstanding at such time does not exceed 10% of our total assets
on a consolidated basis.
Limitation
on Sale and Lease-Back Transactions
Sale and lease-back transactions, except such transactions
involving leases for less than three years, by us or any
Consolidated Subsidiary of any assets are prohibited unless
(a) we or such Consolidated Subsidiary would be entitled to
incur Indebtedness secured by a lien on the assets to be leased
in an amount at least equal to the Attributable Debt in respect
of such transaction without equally and ratably securing the
notes, or (b) the proceeds of the sale of the assets to be
leased are at least equal to their fair market value (as
determined by our Board of Directors) and the proceeds are
applied to the purchase or acquisition, or, in the case of real
property, the construction, of assets or to the retirement of
Indebtedness. The foregoing limitation
S-13
will not apply, if at the time we or any Consolidated Subsidiary
enters into such sale and lease-back transaction, and after
giving effect thereto, Exempted Debt does not exceed 10% of our
total assets on a consolidated basis.
Consolidation,
Merger or Sale
We cannot consolidate or merge with or into, or transfer or
lease all or substantially all of our assets to, any person
unless (a) we will be the continuing corporation or
(b) the successor corporation or person formed by such
consolidation or into which we are merged or to which our assets
substantially as an entirety are transferred or leased is a
corporation, limited liability company or limited partnership
organized or existing under the laws of the United States, any
state of the United States or the District of Columbia and, if
such entity is not a corporation, a co-obligor of the notes is a
corporation organized or existing under any such laws, and such
successor corporation or person, including such co-obligor, if
any, expressly assumes our obligations on the notes and under
the indenture. In addition, we cannot effect such a transaction
unless immediately after giving effect to such transaction, no
default or event of default under the indenture shall have
occurred and be continuing. Subject to certain exceptions, when
the person to whom our assets are transferred or leased has
assumed our obligations under the notes and the indenture, we
shall be discharged from all our obligations under the notes and
the indenture, except in limited circumstances.
This covenant would not apply to any recapitalization
transaction, a change of control of us or a highly leveraged
transaction, unless the transaction or change of control were
structured to include a merger or consolidation or transfer or
lease of all or substantially all of our assets.
Book-Entry
System
The certificates representing the notes of each series will be
issued in the form of one or more fully registered global notes
without coupons (the Global Note) and will be
deposited with, or on behalf of, DTC and registered in the name
of Cede & Co., as the nominee of DTC. Except in
limited circumstances, the notes will not be issuable in
definitive form. Unless and until they are exchanged in whole or
in part for the individual notes represented thereby, any
interests in the Global Note may not be transferred except as a
whole by DTC to a nominee of DTC or by a nominee of DTC to DTC
or another nominee of DTC or by DTC or any nominee of DTC to a
successor depository or any nominee of such successor. See
Description of Debt Securities Registered
Global Securities in the accompanying prospectus.
DTC has advised us that DTC is a limited-purpose trust company
organized under the New York Banking Law, a banking
organization within the meaning of the New York Banking
Law, a member of the Federal Reserve System, a clearing
corporation within the meaning of the New York Uniform
Commercial Code, and a clearing agency registered
pursuant to the provisions of Section 17A of the Exchange
Act. DTC holds securities that its participants (Direct
Participants) deposit with DTC. DTC also facilitates the
post-trade settlement among Direct Participants of sales and
other securities transactions in deposited securities, through
electronic computerized book-entry transfers and pledges between
Direct Participants accounts. This eliminates the need for
physical movement of securities certificates. Direct
Participants include both U.S. and
non-U.S. securities
brokers and dealers, banks, trust companies, clearing
corporations, and certain other organizations. DTC is a wholly
owned subsidiary of The Depository Trust & Clearing
Corporation (DTCC). DTCC is the holding company for
DTC, National Securities Clearing Corporation and Fixed Income
Clearing Corporation, all of which are registered clearing
agencies. DTCC is owned by the users of its regulated
subsidiaries. Access to the DTC system is also available to
others such as both U.S. and
non-U.S. securities
brokers and dealers, banks, trust companies and clearing
corporations that clear through or maintain a custodial
relationship with a Direct Participant, either directly or
indirectly. The rules applicable to DTC and its Participants are
on file with the SEC.
The information in this section concerning DTC and DTCs
book-entry system has been obtained from sources that we believe
to be reliable, but we take no responsibility for the accuracy
thereof.
S-14
Same-Day
Funds Settlement and Payment
Settlement for the notes will be made by the underwriters in
immediately available funds. All payments of principal, premium
if any, and interest in respect of notes in book-entry form will
he made by us in immediately available funds to the accounts
specified by DTC.
Concerning
the Trustee
Wells Fargo Bank, National Association is the trustee under the
indenture with respect to the notes of each series offered
hereby. We may maintain deposit accounts or conduct other
banking transactions with the trustee in the ordinary course of
business.
S-15
UNITED
STATES FEDERAL INCOME TAX CONSEQUENCES
The following is a summary of certain U.S. federal income
tax consequences of the acquisition, ownership, and disposition
of the notes to Non-U.S. Holders (as defined below). This
summary is for informational purposes only and is based on the
Internal Revenue Code of 1986 (the Code), Treasury
Regulations promulgated thereunder, and administrative and
judicial interpretations and practice, all as in effect on the
date of this prospectus supplement and all of which are subject
to change or differing interpretations, with possible
retroactive effect. There can be no assurance that the Internal
Revenue Service (IRS) would not assert, or that a
court would not sustain, positions different from those
discussed herein.
The following discussion does not address foreign, state, or
local tax consequences of the acquisition, ownership, or
disposition of the notes, nor does it address U.S. federal
income tax consequences relevant to special classes of
taxpayers, e.g., dealers in securities; traders in
securities that have elected the mark-to-market method of
accounting for their securities; persons holding notes as part
of a hedge, straddle, conversion or other synthetic
security or integrated transaction; certain
U.S. expatriates; financial institutions; insurance
companies; controlled foreign corporations; passive foreign
investment companies; persons subject to the alternative minimum
tax; entities which are tax-exempt for U.S. federal income
tax purposes.
For purposes of this discussion, a
Non-U.S. Holder is a holder of a note that is
an individual, corporation, estate or trust that is not
(i) a citizen or individual resident of the United States;
(ii) a corporation (or other entity classified as a
corporation for U.S. federal income tax purposes) created,
organized, or domesticated under the laws of the United States
or any political subdivision thereof; (iii) an estate, the
income of which is subject to U.S. federal income taxation
regardless of its source; or (iv) a trust that (a) is
subject to the primary supervision of a U.S. court and has
one or more U.S. persons, within the meaning of Code
section 7701(a)(30), who have the authority to control all
substantial decisions of the trust, or (b) has a valid
election in effect under applicable Treasury regulations to be
treated as a U.S. person.
If a partnership (or an entity treated as a partnership for
United States federal income tax purposes) holds notes, the
U.S. federal income tax treatment of a partner in such
partnership will generally depend on the status of the partner
and the activities of the partnership. Such a partner or
partnership should consult its tax advisors as to the tax
consequences of an investment in the notes.
Prospective holders should consult an independent tax advisor
with respect to the U.S. federal, state, local and foreign
tax consequences of acquiring, owning, or disposing of the notes
in light of their particular circumstances as well as with
respect to any tax consequences of acquiring, owning, or
disposing of the notes under U.S. federal estate or gift
tax laws or under any applicable tax treaty.
Payments
of interest
It is expected, and, therefore, this summary assumes that the
notes will not be issued with original issue discount for U.S.
federal income tax purposes. Generally, any interest paid to a
Non-U.S. Holder
of a note that is not effectively connected with a
U.S. trade or business will not be subject to
U.S. federal income (including withholding) tax if the
interest qualifies as portfolio interest. Interest
on the notes generally will qualify as portfolio interest if
(a) the
Non-U.S. Holder
does not actually or constructively own 10% or more of the total
voting power of all our voting stock, (b) such holder is
not a controlled foreign corporation with respect to
which we are a related person within the meaning of
the Code, and (c) either the beneficial owner, under
penalties of perjury, certifies that the beneficial owner is not
a U.S. person and such certificate provides the beneficial
owners name and address, or a securities clearing
organization, bank or other financial institution that holds
customers securities in the ordinary course of its trade
or business and holds the notes certifies, under penalties of
perjury, that such statement has been received from the
beneficial owner by it or by a financial institution between it
and the beneficial owner. The gross amount of payments to a
Non-U.S. Holder
of interest that is not effectively connected with a
U.S. trade or business and that does not qualify for the
portfolio interest exemption will be subject to
U.S. withholding tax at the rate of 30%, unless a
U.S. income tax treaty applies to reduce or eliminate such
withholding tax. Payments of interest that are effectively
connected with the conduct of a U.S. trade or business by a
Non-U.S. Holder
and, to the extent an applicable treaty so provides, are
attributable to a permanent establishment (or, in the case of an
individual, a fixed base)
S-16
in the United States will be taxed on a net basis at regular
U.S. rates in the same manner as such payments to
U.S. Holders. In the case of a
Non-U.S. Holder
that is a corporation, such effectively connected income may
also be subject to the branch profits tax (which is generally
imposed on a foreign corporation on the actual or deemed
repatriation from the United States of earnings and profits
attributable to U.S. trade or business income) at a 30%
rate. The branch profits tax may not apply (or may apply at a
reduced rate) if a recipient is a qualified resident of certain
countries with which the United States has an income tax treaty.
If payments of interest are effectively connected with a
Non-U.S. Holders
conduct of a U.S. trade or business (whether or not a
treaty applies), the 30% withholding tax discussed above will
not apply provided the appropriate certification (discussed
below) is provided. To claim the benefit of a tax treaty or to
claim exemption from withholding because the income is
effectively connected with a
Non-U.S. Holders
conduct of a U.S. trade or business, the
non-U.S. holder
must provide a properly executed IRS
Form W-8BEN
or W-8ECI
(or such successor forms as the IRS may designate), as
applicable, prior to the payment of interest. These forms must
be periodically updated. A
Non-U.S. Holder
that is claiming the benefits of a treaty may be required in
certain instances to obtain a U.S. taxpayer identification
number and to provide certain documentary evidence issued by
foreign governmental authorities to prove residence in the
foreign country.
Sale,
exchange, redemption or other disposition
A
Non-U.S. Holder
generally will not be subject to U.S. federal income tax
with respect to any gain realized on the sale, exchange,
redemption or other disposition of a note unless: (i) the
Non-U.S. Holder
is a nonresident alien individual who is present in the United
States for a period or periods aggregating 183 or more days in
the taxable year of the disposition and certain other conditions
are met, in which case the
Non-U.S. Holder
will be subject to a flat 30% U.S. federal income tax on
any gain recognized (except to the extent otherwise provided by
an applicable income tax treaty), which may be offset by certain
U.S. losses; or (ii) such gain is effectively
connected with the conduct of a U.S. trade or business by a
Non-U.S. Holder
and, to the extent an applicable treaty so provides, is
attributable to a permanent establishment (or, in the case of an
individual, a fixed base) in the United States, in which case
such gain will be taxable in the same manner as effectively
connected interest (discussed above).
Information
reporting and backup withholding
A Non-U.S. Holder may be required to certify under
penalties of perjury that it is a Non-U.S. Holder
(generally through the provision of a properly executed IRS
Form W-8BEN) in order to prevent information reporting and
backup withholding. Backup withholding is not an additional
tax. Any amounts withheld from payments to a
Non-U.S. Holder under the backup withholding rules may be
refunded or credited against a Non-U.S. Holders federal
income tax liability, if any, if the holder timely provides the
required information to the IRS.
S-17
UNDERWRITING
Subject to the terms and conditions contained in an underwriting
agreement, dated as of the date of this prospectus
supplement between us and the underwriters named below, for whom
J.P. Morgan Securities LLC and Merrill Lynch, Pierce,
Fenner & Smith Incorporated are acting as
representatives, we have agreed to sell to each underwriter, and
each underwriter has agreed, severally and not jointly, to
purchase from us, the principal amount of notes that appears
opposite its name in the table below:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Principal Amount
|
|
|
Principal Amount
|
|
|
Principal Amount
|
|
Underwriter
|
|
of 2016 Notes
|
|
|
of 2021 Notes
|
|
|
of 2041 Notes
|
|
|
J.P. Morgan Securities LLC
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
Merrill Lynch, Pierce, Fenner & Smith
Incorporated
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The underwriters are offering the notes subject to their
acceptance of the notes from us and subject to prior sale. The
underwriting agreement provides that the obligations of the
several underwriters to pay for and accept delivery of the notes
offered by this prospectus supplement are subject to certain
conditions. The underwriters are obligated to take and pay for
all of the notes offered by this prospectus supplement if any
such notes are taken.
The underwriters initially propose to offer the notes to the
public at the public offering prices that appear on the cover
page of this prospectus supplement. In addition, the
underwriters initially propose to offer the notes to certain
dealers at the public offering prices less a concession not to
exceed % of the principal amount,
with respect to the 2016 notes, %
of the principal amount, with respect to the 2021 notes,
and % of the principal amount, with
respect to the 2041 notes. Any underwriter may allow, and any
such dealer may reallow, a concession not to
exceed % of the principal amount,
with respect to the 2016 notes, %
of the principal amount, with respect to the 2021 notes,
and % of the principal amount, with
respect to the 2041 notes on sales to certain other dealers.
After the initial offering of the notes to the public, the
representatives may change the public offering prices and
concessions. The underwriters may from time to time vary the
offering prices and other selling terms. The underwriters may
offer and sell notes through certain of their affiliates.
The following table shows the underwriting discounts that we
will pay to the underwriters in connection with the offering of
the notes:
|
|
|
|
|
|
|
|
|
|
|
|
|
Paid by us
|
|
2016 Notes
|
|
2021 Notes
|
|
2041 Notes
|
|
Per note
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
|
|
|
|
|
|
|
|
|
|
|
Expenses associated with this offering to be paid by us, other
than underwriting discounts, are estimated to be approximately
$ .
We have also agreed to indemnify the underwriters against
certain liabilities, including liabilities under the Securities
Act, or to contribute to payments which the underwriters may be
required to make in respect of any such liabilities.
The notes are new issues of securities, and there are currently
no established trading markets for the notes. We do not intend
to apply for the notes to be listed on any securities exchange
or for quotation on any automated dealer quotation system. The
underwriters have advised us that they intend to make a market
in the notes, but they are not obligated to do so. The
underwriters may discontinue any market making in the notes at
any time at their sole discretion. Accordingly, we cannot assure
you that liquid trading markets will develop for the notes, that
you will be able to sell your notes at a particular time or that
the prices you receive when you sell will be favorable.
In connection with the offering of the notes, the underwriters
may engage in transactions that stabilize, maintain or otherwise
affect the prices of the notes. Specifically, the underwriters
may overallot in connection
S-18
with the offering of the notes, creating syndicate short
positions. In addition, the underwriters may bid for and
purchase notes in the open market to cover syndicate short
positions or to stabilize the prices of the notes. Finally, the
underwriting syndicate may reclaim selling concessions allowed
for distributing the notes in the offering of the notes, if the
syndicate repurchases previously distributed notes in syndicate
covering transactions, stabilization transactions or otherwise.
Any of these activities may stabilize or maintain the market
prices of the notes above independent market levels. However,
neither we nor the underwriters make any representation or
prediction as to the direction or magnitude of any effect that
these activities may have on the price of the notes. In
addition, the underwriters are not required to engage in any of
these activities, and may end any of them at any time.
Conflicts
of Interest
From time to time in the ordinary course of their respective
businesses, certain of the underwriters and their affiliates
have engaged in and may in the future engage in commercial
banking, derivatives
and/or
financial advisory, investment banking and other commercial
transactions and services with us and our affiliates for which
they have received or will receive customary fees and
commissions. In particular, the representatives of the
underwriters serve as joint bookrunners and joint lead arrangers
under the Bridge Loan, and affiliates of the representatives
serve as administrative agent and syndication agent. In
addition, certain of the underwriters or their affiliates are
agents
and/or
lenders under the Bridge Loan. As described in Use of
Proceeds, a portion of the net proceeds from this offering
may be used to repay outstanding borrowings under the Bridge
Loan. As affiliates of J.P. Morgan Securities LLC and
Merrill Lynch, Pierce, Fenner & Smith Incorporated may
each receive more than 5% of the proceeds of this offering, not
including underwriting compensation, J.P. Morgan Securities
LLC and Merrill Lynch, Pierce, Fenner & Smith
Incorporated each may have a conflict of interest as
defined in Rule 5121 adopted by the Financial Industry
Regulatory Authority. Consequently, this offering will be
conducted in accordance with Rule 5121. No underwriter
having a conflict of interest will confirm sales to accounts
over which discretionary authority is exercised without the
prior written consent of the accountholder. In accordance with
Rule 5121, a qualified independent underwriter
is not required because the notes offered are investment grade
rated, as that term is defined in Rule 5121.
In addition, in the ordinary course of their business
activities, the underwriters and their affiliates may make or
hold a broad array of investments and actively trade debt and
equity securities (or related derivative securities) and
financial instruments (including bank loans) for their own
account and for the accounts of their customers. Such
investments and securities activities may involve securities
and/or
instruments of ours or our affiliates. The underwriters and
their affiliates may also make investment recommendations
and/or
publish or express independent research views in respect of such
securities or financial instruments and may hold, or recommend
to clients that they acquire, long
and/or short
positions in such securities and instruments.
Selling
Restrictions
European
Economic Area
In relation to each Member State of the European Economic Area
which has implemented the Prospectus Directive (each, a
Relevant Member State), with effect from and
including the date on which the Prospectus Directive is
implemented in that Relevant Member State (the Relevant
Implementation Date) offers of notes which are the subject
of the offering contemplated by this prospectus supplement may
not be made to the public in that Relevant Member State other
than:
(a) to any legal entity which is a qualified investor as
defined in the Prospectus Directive;
(b) to fewer than 100 or, if the Relevant Member State has
implemented the relevant provision of the 2010 PD Amending
Directive, 150, natural or legal persons (other than qualified
investors as defined in the Prospectus Directive), as permitted
under the Prospectus Directive, subject to obtaining the prior
consent of the representatives for any such offer; or
(c) in any other circumstances falling within
Article 3(2) of the Prospectus Directive,
S-19
provided that no such offer of notes shall require us or any
underwriter to publish a prospectus pursuant to Article 3
of the Prospectus Directive.
For the purposes of this provision, the expression an
offer of notes to the public in relation to any
notes in any Relevant Member State means the communication in
any form and by any means of sufficient information on the terms
of the offer and the notes to be offered so as to enable an
investor to decide to purchase or subscribe for the notes, as
the same may be varied in that Member State by any measure
implementing the Prospectus Directive in that Member State, the
expression Prospectus Directive means Directive
2003/71/EC (and amendments thereto, including the 2010 PD
Amending Directive, to the extent implemented in the Relevant
Member State), and includes any relevant implementing measure in
the Relevant Member State and the expression 2010 PD
Amending Directive means Directive 2010/73/EU.
United
Kingdom
Each underwriter has advised us that:
(a) it has only communicated or caused to be communicated
and will only communicate or cause to be communicated an
invitation or inducement to engage in investment activity
(within the meaning of Section 21 of the Financial Services
and Markets Act (FSMA)) received by it in connection
with the issue or sale of the notes in circumstances in which
Section 21(1) of the FSMA does not apply to us; and
(b) it has complied and will comply with all applicable
provisions of the FSMA with respect to anything done by it in
relation to the notes in, from or otherwise involving the United
Kingdom.
S-20
VALIDITY
OF THE NOTES
The validity of the notes offered hereby will be passed upon for
us by Skadden, Arps, Slate, Meagher & Flom LLP, Los
Angeles, California, and for the underwriters by Davis
Polk & Wardwell LLP, New York, New York.
EXPERTS
The consolidated financial statements, the related financial
statement schedule, incorporated in this prospectus supplement
by reference from our Annual Report on
Form 10-K
for the fiscal year ended March 31, 2010, and the
effectiveness of our internal control over financial reporting
have been audited by Deloitte & Touche LLP, an
independent registered public accounting firm, as stated in
their report, which is incorporated herein by reference. Such
financial statements and financial statement schedule have been
so incorporated in reliance upon the report of such firm given
upon their authority as experts in accounting and auditing.
WHERE YOU
CAN FIND MORE INFORMATION
The SEC allows us to incorporate by reference into
this prospectus supplement the information we file with the SEC,
which means:
|
|
|
|
|
incorporated documents are considered part of this prospectus
supplement;
|
|
|
|
we can disclose important information to you by referring you to
those documents; and
|
|
|
|
information we file with the SEC will automatically update and
supersede the information in this prospectus supplement and any
information that was previously incorporated.
|
We incorporate by reference the documents listed below and any
future documents we file with the SEC under Sections 13(a),
13(c), 14 or 15(d) of the Exchange Act, until we terminate this
offering (excluding any information furnished and not filed
pursuant to Items 2.02 or 7.01 on any Current Report on
Form 8-K):
|
|
|
|
|
our Annual Report on
Form 10-K
for the fiscal year ended March 31, 2010;
|
|
|
|
our Quarterly Reports on
Form 10-Q
for the quarters ended June 30, 2010, September 30,
2010 and December 31, 2010; and
|
|
|
|
our Current Reports on
Form 8-K
filed on May 18, 2010, August 3, 2010,
October 19, 2010, November 3, 2010 and
November 29, 2010.
|
You can obtain any of the filings incorporated by reference in
this document through us, or from the SEC through the SECs
web site at
http://www.sec.gov
or at the SECs Public Reference Room at
100 F Street, N.E., Washington, DC 20549. You may
obtain information on the operation of the SECs Public
Reference Room by calling
1-800-SEC-0330.
Documents incorporated by reference are available from us
without charge, excluding any exhibits to those documents unless
the exhibit is specifically incorporated by reference as an
exhibit in this prospectus supplement. You can obtain documents
incorporated by reference in this prospectus supplement by
requesting them in writing or by telephone from us at the
following address:
McKesson Corporation
One Post Street
San Francisco, California 94104
Attn: Corporate Secretary
Telephone:
(415) 983-8300
Any statement contained in a document incorporated by reference
herein shall be deemed to be modified or superseded for purposes
of the prospectus supplement to the extent that a statement
contained herein or in any other subsequently filed document
that is incorporated by reference herein modifies or supersedes
such earlier statement. Any such statement so modified or
superseded shall not be deemed, except as so modified or
superseded, to constitute a part of the prospectus supplement.
S-21
McKESSON CORPORATION
COMMON STOCK
PREFERRED STOCK
DEPOSITARY SHARES
DEBT SECURITIES
WARRANTS
STOCK PURCHASE
CONTRACTS
STOCK PURCHASE UNITS
McKESSON
CORPORATION
|
|
|
|
|
may sell common stock;
|
|
|
|
may sell preferred stock;
|
|
|
|
may sell depositary shares representing preferred stock;
|
|
|
|
may sell debt securities;
|
|
|
|
may sell warrants; and
|
|
|
|
may sell stock purchase contracts or stock purchase units.
|
The common stock of McKesson Corporation is listed on the New
York Stock Exchange under the symbol MCK. Our
principal executive offices are located at McKesson Plaza, One
Post Street, San Francisco, California 94104, and our
telephone number is
(415) 983-8300.
We urge you to read carefully this prospectus and the
accompanying prospectus supplement, which will describe the
specific terms of the securities being offered to you, before
you make your investment decision.
NEITHER THE SECURITIES AND EXCHANGE COMMISSION NOR ANY STATE
SECURITIES COMMISSION HAS APPROVED OR DISAPPROVED OF THESE
SECURITIES OR DETERMINED IF THIS PROSPECTUS OR THE ACCOMPANYING
PROSPECTUS SUPPLEMENT IS TRUTHFUL OR COMPLETE. ANY
REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE.
This prospectus may not be used to sell securities unless
accompanied by a prospectus supplement.
The date of this prospectus is February 9, 2009.
TABLE OF
CONTENTS
|
|
|
|
|
|
|
Page
|
|
Page
|
|
|
|
|
|
|
|
1
|
|
|
|
|
1
|
|
|
|
|
2
|
|
|
|
|
2
|
|
|
|
|
2
|
|
|
|
|
3
|
|
|
|
|
3
|
|
|
|
|
7
|
|
|
|
|
10
|
|
|
|
|
18
|
|
|
|
|
20
|
|
|
|
|
20
|
|
|
|
|
22
|
|
|
|
|
22
|
|
Unless otherwise indicated or the context otherwise requires,
all references in this prospectus to McKesson,
the company, we, our,
us or similar terms refer to McKesson Corporation,
together with its subsidiaries.
ABOUT
THIS PROSPECTUS
This prospectus is part of a shelf registration
statement that we filed with the Securities and Exchange
Commission (the Commission or SEC). By
using a shelf registration statement, we may sell, from time to
time, in one or more offerings, any combination of the
securities described in this prospectus.
This prospectus provides you with a general description of the
securities we may offer. Each time we sell securities, we will
provide a prospectus supplement that will contain specific
information about the terms of that offering. The accompanying
prospectus supplement may also add, update or change information
contained in this prospectus. You should read both this
prospectus and the accompanying prospectus supplement together
with additional information described under the heading
Where You Can Find More Information.
We may include agreements as exhibits to the registration
statement of which this prospectus forms a part. In reviewing
such agreements, please remember they are included to provide
you with information regarding their terms and are not intended
to provide any other factual or disclosure information about us
or the other parties to the agreements. The agreements may
contain representations and warranties by each of the parties to
the applicable agreement. These representations and warranties
have been made solely for the benefit of the other parties to
the applicable agreement and:
|
|
|
|
|
should not in all instances be treated as categorical statements
of fact, but rather as a way of allocating the risk to one of
the parties if those statements prove to be inaccurate;
|
|
|
|
may have been qualified by disclosures that were made to the
other party in connection with the negotiation of the applicable
agreement, which disclosures would not necessarily be reflected
in the agreement;
|
|
|
|
may apply standards of materiality in a way that is different
from what may be viewed as material to you or other
investors; and
|
|
|
|
were made only as of the date of the applicable agreement or
such other date or dates as may be specified in the agreement
and are subject to more recent developments.
|
Accordingly, these representations and warranties may not
describe the actual state of affairs as of the date they were
made or at any other time. Additional information about us may
be found elsewhere in the registration statement of which this
prospectus forms a part and our other public filings, which are
available without charge through the SECs website at
http://www.sec.gov.
WHERE YOU
CAN FIND MORE INFORMATION
We file reports, proxy statements, and other information with
the SEC. Such reports, proxy statements, and other information
concerning us can be read and copied at the SECs Public
Reference Room at 100 F Street, N.E., Room 1580,
Washington, D.C. 20549 or on the Internet at
http://www.sec.gov.
Please call the SEC at
1-800-SEC-0330
for further information on the Public Reference Room. Our common
stock is listed on the New York Stock Exchange, and these
reports, proxy statements and other information are also
available for inspection at the offices of the New York Stock
Exchange, 20 Broad Street, New York, New York 10005.
This prospectus is part of a registration statement filed with
the SEC by us. The full registration statement can be obtained
from the SEC as indicated above, or from us.
The SEC allows us to incorporate by reference the
information we file with the SEC. This permits us to disclose
important information to you by referring to these filed
documents. Any information referred to in this way is considered
part of this prospectus, and any information filed with the SEC
by us after the date of
1
this prospectus will automatically be deemed to update and
supersede this information. We incorporate by reference the
following documents that have been filed with the SEC (other
than information in such documents that is not deemed to be
filed):
|
|
|
|
|
Annual Report on
Form 10-K
for the fiscal year ended March 31, 2008;
|
|
|
|
Quarterly Reports on
Form 10-Q
for the quarters ended June 30, 2008, September 30,
2008 and December 31, 2008; and
|
|
|
|
Current Reports on
Form 8-K
filed on April 28, 2008, July 29, 2008 and
November 21, 2008.
|
We also incorporate by reference any future filings (other than
information in such documents that is not deemed to be filed)
made with the SEC pursuant to Section 13(a), 13(c), 14 or
15(d) of the Securities Exchange Act of 1934, as amended (the
Exchange Act), until we file a post-effective
amendment which indicates the termination of the offering of the
securities made by this prospectus.
We will provide without charge upon written or oral request a
copy of any or all of the documents that are incorporated by
reference into this prospectus, other than exhibits which are
specifically incorporated by reference into such documents.
Requests should be directed to our Corporate Secretary at
McKesson Corporation, McKesson Plaza, One Post Street,
San Francisco, California 94104. Our telephone number is
(415) 983-8300.
SPECIAL
NOTE REGARDING FORWARD-LOOKING STATEMENTS
This prospectus and the documents incorporated by reference
herein include forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933, as amended (the
Securities Act), and Section 21E of the
Exchange Act. Some of the forward-looking statements can be
identified by the use of forward-looking words such as
believes, expects,
anticipates, may, should,
seeks, approximately,
intends, plans, or
estimates, or the negative of these words, or other
comparable terminology. Forward-looking statements involve risks
and uncertainties that could cause actual results to differ
materially from those projected, anticipated or implied.
Although it is not possible to predict or identify all such
risks and uncertainties, they may include, but are not limited
to, the factors discussed under Risk Factors in our
Annual Reports on
Form 10-K,
in our Quarterly Reports on
Form 10-Q,
in any prospectus supplement related hereto, and in other
information contained in our publicly available SEC filings and
press releases. You should not consider this list to be a
complete statement of all risks and uncertainties. You are
cautioned not to place undue reliance on any such
forward-looking statements, which speak only as of the date such
statements were first made. Except to the extent required by
federal securities laws, we undertake no obligation to publicly
release the result of any revisions to these forward-looking
statements to reflect events or circumstances after the date
hereof or to reflect the occurrence of unanticipated events.
McKESSON
CORPORATION
McKesson Corporation is a healthcare services and information
technology company providing supply, information and care
management products and services designed to reduce costs and
improve quality across the healthcare industry. We conduct our
business through two segments: McKesson Distribution Solutions
and McKesson Technology Solutions.
Our principal executive offices are located at McKesson Plaza,
One Post Street, San Francisco, California 94104, and our
telephone number is
(415) 983-8300.
USE OF
PROCEEDS
Unless otherwise set forth in a prospectus supplement with
respect to the proceeds from the sale of the particular
securities to which such prospectus supplement relates, we
intend to use the net proceeds from the sale of the offered
securities for general corporate purposes, including repayment
or redemption of outstanding
2
debt or preferred stock, the possible acquisition of related
businesses or assets thereof, and working capital needs.
RATIO OF
EARNINGS TO FIXED CHARGES
No shares of our preferred stock were outstanding during the
years ended March 31, 2008, 2007, 2006, 2005 and 2004, or
during the nine months ended December 31, 2008. Therefore,
the ratios of earnings to fixed charges and preferred dividends
are not separately stated from the ratios of earnings to fixed
charges for the periods listed above. The table below reflects
our ratio of earnings to fixed charges for the nine months ended
December 31, 2008, and each of the five years in the period
ended March 31, 2008.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the Nine
|
|
|
|
|
|
|
|
|
|
|
|
|
Months Ended
|
|
For the Year
|
|
|
December 31,
|
|
Ended March 31,
|
|
|
2008
|
|
2008
|
|
2007
|
|
2006
|
|
2005
|
|
2004
|
|
Ratio of earnings to fixed charges(a)
|
|
|
5.7
|
|
|
|
8.3
|
|
|
|
10.1
|
|
|
|
9.7
|
|
|
|
(b
|
)
|
|
|
6.5
|
|
|
|
|
(a) |
|
The ratio of earnings to fixed charges was computed by dividing
earnings by fixed charges. For this purpose,
earnings consists of pre-tax income/(loss) from
continuing operations plus fixed charges; and fixed
charges consists of interest costs, both expensed and
capitalized (including amortization of debt discounts and
deferred loan costs), and the interest component of rent expense. |
|
(b) |
|
Earnings for the year ended March 31, 2005 were inadequate
to cover fixed charges. The coverage deficiency was
$276 million for the ratio of earnings to fixed charges. |
DESCRIPTION
OF SECURITIES
This prospectus contains a summary of our common stock,
preferred stock, depositary shares, debt securities, warrants,
stock purchase contracts and stock purchase units. These
summaries are not meant to be a complete description of each
security. The particular terms of any security to be issued
pursuant hereto will be set forth in a related prospectus
supplement. This prospectus and the accompanying prospectus
supplement will contain the material terms and conditions for
each security.
DESCRIPTION
OF CAPITAL STOCK
The following descriptions of our capital stock and of certain
provisions of Delaware law do not purport to be complete and are
subject to and qualified in their entirety by reference to our
amended and restated certificate of incorporation, our amended
and restated by-laws and the Delaware General Corporation Law
(DGCL). Copies of our amended and restated
certificate of incorporation and our amended and restated
by-laws have been filed with the SEC and are filed as exhibits
to the registration statement of which this prospectus forms a
part.
As of the date hereof, our authorized capital stock consists of
900,000,000 shares, of which 800,000,000 shares are
common stock, par value $0.01 per share, and
100,000,000 shares are preferred stock, par value $0.01 per
share. As of December 31, 2008, there were
273,832,171 shares of common stock issued and outstanding,
and no shares of preferred stock issued and outstanding. Of the
preferred stock, 10,000,000 shares have been designated
Series A Junior Participating Preferred Stock. All of our
outstanding shares of common stock are fully paid and
non-assessable.
Our common stock is listed on the New York Stock Exchange under
the symbol MCK.
Common
Stock
Dividend Rights. Subject to the dividend
rights of the holders of any outstanding preferred stock, the
holders of shares of common stock are entitled to receive
ratably dividends out of assets legally available therefor at
such times and in such amounts as our board of directors may
from time to time determine.
3
Rights Upon Liquidation. Upon liquidation,
dissolution or winding up of our affairs, the holders of common
stock are entitled to share ratably in our assets that are
legally available for distribution, after payment of all debts,
other liabilities and any liquidation preferences of outstanding
preferred stock.
Conversion, Redemption and Preemptive
Rights. Holders of our common stock have no
conversion, redemption, preemptive or similar rights.
Voting Rights. Each outstanding share of
common stock is entitled to one vote on all matters submitted to
a vote of stockholders. Our amended and restated certificate of
incorporation does not provide for cumulative voting in the
election of directors.
Preferred
Stock
Our amended and restated certificate of incorporation authorizes
our board of directors, without further stockholder action, to
provide for the issuance of up to 100,000,000 shares of
preferred stock, in one or more series, and to fix the
designations, terms, and relative rights and preferences,
including the dividend rate, voting rights, conversion rights,
redemption and sinking fund provisions and liquidation
preferences of each of these series. We may amend from time to
time our amended and restated certificate of incorporation to
increase the number of authorized shares of preferred stock. Any
such amendment would require the approval of the holders of a
majority of our shares entitled to vote.
The particular terms of any series of preferred stock that we
offer under this prospectus will be described in the applicable
prospectus supplement relating to that series of preferred
stock. Those terms may include:
|
|
|
|
|
the title and liquidation preference per share of the preferred
stock and the number of shares offered;
|
|
|
|
the purchase price of the preferred stock;
|
|
|
|
the dividend rate (or method of calculation), the dates on which
dividends will be payable, whether dividends shall be cumulative
and, if so, the date from which dividends will begin to
accumulate;
|
|
|
|
any redemption or sinking fund provisions of the preferred stock;
|
|
|
|
any conversion, redemption or exchange provisions of the
preferred stock;
|
|
|
|
the voting rights, if any, of the preferred stock; and
|
|
|
|
any additional dividend, liquidation, redemption, sinking fund
and other rights, preferences, privileges, limitations and
restrictions of the preferred stock.
|
If the terms of any series of preferred stock being offered
differ from the terms set forth in this prospectus, those terms
will also be disclosed in the applicable prospectus supplement
relating to that series of preferred stock. The summary in this
prospectus is not complete. You should refer to the certificate
of designations establishing a particular series of preferred
stock which will be filed with the Secretary of State of the
State of Delaware and the SEC in connection with the offering of
the preferred stock.
Each prospectus supplement may describe certain
U.S. federal income tax considerations applicable to the
purchase, holding and disposition of the preferred stock that
prospectus supplement covers.
Dividend Rights. The preferred stock will be
preferred over the common stock as to payment of dividends.
Before any dividends or distributions (other than dividends or
distributions payable in common stock or other stock ranking
junior to that series of preferred stock as to dividends and
upon liquidation) on the common stock or other stock ranking
junior to that series of preferred stock as to dividends and
upon liquidation shall be declared and set apart for payment or
paid, the holders of shares of each series of preferred stock
(unless otherwise set forth in the applicable prospectus
supplement) will be entitled to receive dividends when, as and
if declared by our board of directors or, if dividends are
cumulative, full cumulative dividends for the current and all
prior dividend periods. We will pay those dividends either in
cash, shares of preferred stock, or otherwise, at the rate and
on the date or dates set forth in the applicable prospectus
supplement. With respect to each series of preferred stock that
has cumulative dividends, the dividends on each share of the
series will be cumulative from the date of issue of the share
unless some other date is set
4
forth in the prospectus supplement relating to the series.
Accruals of dividends will not bear interest. The applicable
prospectus supplement will indicate the relative ranking of the
particular series of the preferred stock as to the payment of
dividends, as compared with then-existing and future series of
preferred stock.
Rights Upon Liquidation. The preferred stock
of each series will be preferred over the common stock and other
stock ranking junior to that series of preferred stock as to
assets, so that the holders of that series of preferred stock
(unless otherwise set forth in the applicable prospectus
supplement) will be entitled to be paid, upon our voluntary or
involuntary liquidation, dissolution or winding up, and before
any distribution is made to the holders of common stock and
other stock ranking junior to that series of preferred stock,
the amount set forth in the applicable prospectus supplement.
However, in this case the holders of preferred stock of that
series will not be entitled to any other or further payment. If
upon any liquidation, dissolution or winding up, our net assets
are insufficient to permit the payment in full of the respective
amounts to which the holders of all outstanding preferred stock
are entitled, our entire remaining net assets will be
distributed among the holders of each series of preferred stock
in amounts proportional to the full amounts to which the holders
of each series are entitled, subject to any provisions of any
series of preferred stock that rank it junior or senior to other
series of preferred stock upon liquidation. The applicable
prospectus supplement will indicate the relative ranking of the
particular series of the preferred stock upon liquidation, as
compared with then-existing and future series of preferred stock.
Conversion, Redemption or Exchange Rights. The
shares of a series of preferred stock will be convertible at the
option of the holder of the preferred stock, redeemable at our
option or the option of the holder, as applicable, or
exchangeable at our option, into another security, in each case,
to the extent set forth in the applicable prospectus supplement.
Voting Rights. Except as indicated in the
applicable prospectus supplement or as otherwise from time to
time required by law, the holders of preferred stock will have
no voting rights.
Anti-Takeover
Effects of Provisions of Our Amended and Restated Certificate of
Incorporation and Our Amended and Restated By-Laws
Our amended and restated certificate of incorporation and our
amended and restated by-laws contain certain provisions that may
be deemed to have an anti-takeover effect and may delay, deter
or prevent a tender offer or takeover attempt that a stockholder
might consider in its best interest, including those attempts
that might result in a premium over the market price for the
shares held by stockholders.
Our amended and restated certificate of incorporation also
provides that any action required or permitted to be taken by
the holders of common stock may be effected only at an annual or
special meeting of such holders, and that stockholders may act
in lieu of such meetings only by unanimous written consent. Our
amended and restated by-laws provide that special meetings of
holders of common stock may be called only by our Chairman or
President or board of directors. Holders of common stock are not
permitted to call a special meeting or to require that our board
of directors call a special meeting of stockholders.
Our amended and restated by-laws establish an advance notice
procedure for the nomination, other than by or at the direction
of our board of directors, of candidates for election as
directors as well as for other stockholder proposals to be
considered at annual meetings of stockholders. In general,
notice of intent to nominate a director or raise business at
such meetings must be received by us not less than 90 nor more
than 120 days prior to the date of the annual meeting and
must contain certain specified information concerning the person
to be nominated or the matters to be brought before the meeting
and concerning the stockholder submitting the proposal.
Our amended and restated certificate of incorporation provides
that certain provisions of our amended and restated by-laws may
only be amended by the affirmative vote of the holders of 75% of
our outstanding shares entitled to vote. Our amended and
restated certificate of incorporation also provides that, in
addition to any affirmative vote required by law, the
affirmative vote of holders of 80% of our outstanding voting
stock and two-thirds of the voting stock other than voting stock
held by an interested stockholder shall be necessary to approve
certain business combinations proposed by an interested
stockholder.
5
The foregoing summary is qualified in its entirety by the
provisions of our amended and restated certificate of
incorporation and our amended and restated by-laws, copies of
which have been filed with the SEC.
Section 203
of Delaware General Corporation Law
We are subject to the business combination statute
of the DGCL. In general, such statute prohibits a publicly held
Delaware corporation from engaging in a business
combination with any interested stockholder
for a period of three years after the date of the transaction in
which the person became an interested stockholder,
unless:
(1) such transaction is approved by our board of directors
prior to the date the interested stockholder obtains such status,
(2) upon consummation of such transaction, the
interested stockholder beneficially owned at least
85% of the voting stock of the corporation outstanding at the
time the transaction commenced, excluding for purposes of
determining the number of shares outstanding those shares owned
by (a) persons who are directors and also officers and
(b) employee stock plans in which employee participants do
not have the right to determine confidentially whether shares
held subject to the plan will be tendered in a tender or
exchange offer, or
(3) the business combination is approved by our
board of directors and authorized at an annual or special
meeting of stockholders by the affirmative vote of at least
66-2/3%
of the outstanding voting stock which is not owned by the
interested stockholder.
A business combination includes mergers, asset sales
and other transactions resulting in financial benefit to the
interested stockholder. An interested
stockholder is a person who, together with affiliates and
associates, owns (or within three years, did own) beneficially
15% or more of a corporations voting stock. The statute
could prohibit or delay mergers or other takeover or change in
control attempts with respect to us and, accordingly, may
discourage attempts to acquire us.
Certain
Effects of Authorized But Unissued Stock
Our authorized but unissued shares of common stock and preferred
stock may be issued without additional stockholder approval and
may be utilized for a variety of corporate purposes, including
future offerings to raise additional capital or to facilitate
corporate acquisitions.
The issuance of preferred stock could have the effect of
delaying or preventing a change in control of us. The issuance
of preferred stock could decrease the amount available for
distribution to holders of our common stock or could adversely
affect the rights and powers, including voting rights, of such
holders. In certain circumstances, such issuance could have the
effect of decreasing the market price of our common stock.
One of the effects of the existence of unissued and unreserved
common stock or preferred stock may be to enable our board of
directors to issue shares to persons friendly to current
management, which could render more difficult or discourage an
attempt to obtain control of us by means of a merger, tender
offer, proxy contest or otherwise, and thereby protect the
continuity of management. Such additional shares also could be
used to dilute the stock ownership of persons seeking to obtain
control of us.
We plan to issue additional shares of common stock in connection
with our employee benefit plans. We do not currently have any
plans to issue shares of preferred stock.
Limitation
of Liability of Directors
Our amended and restated certificate of incorporation contains a
provision that limits the liability of our directors for
monetary damages for breach of fiduciary duty as a director to
the fullest extent permitted by the Delaware General Corporation
Law. Such limitation does not, however, affect the liability of
a director (1) for any breach of the directors duty
of loyalty to us or our stockholders, (2) for acts or
omissions not in good faith or that involve intentional
misconduct or a knowing violation of law, (3) in respect of
certain unlawful
6
dividend payments or stock redemptions or purchases and
(4) for any transaction from which the director derives an
improper personal benefit. The effect of this provision is to
eliminate our rights and the rights of our stockholders (through
stockholders derivative suits) to recover monetary damages
against a director for breach of the fiduciary duty of care as a
director (including breaches resulting from negligent or grossly
negligent behavior) except in the situations described in
clauses (1) through (4) above. This provision does not
limit or eliminate our rights or the rights of our stockholders
to seek non-monetary relief such as an injunction or rescission
in the event of a breach of a directors duty of care. In
addition, our directors and officers have indemnification
protection.
Transfer
Agent and Registrar
Wells Fargo Shareowner Services acts as transfer agent and
registrar of our common stock.
Listing
Our common stock is listed on the New York Stock Exchange under
the symbol MCK.
DESCRIPTION
OF DEPOSITARY SHARES
The following description of the depositary shares does not
purport to be complete and is subject to and qualified in its
entirety by the Deposit Agreement and the depositary receipt
relating to the preferred stock that is attached to the Deposit
Agreement. You should read these documents as they, and not this
description, define your rights as a holder of depositary
shares. Forms of these documents have been filed with the SEC as
an exhibit to the registration statement of which this
prospectus forms a part.
General
If we elect to offer fractional interests in shares of preferred
stock, we will provide for the issuance by a depositary to the
public of receipts for depositary shares. Each depositary share
will represent fractional interests of preferred stock. We will
deposit the shares of preferred stock underlying the depositary
shares under a Deposit Agreement between us and a bank or trust
company selected by us. The bank or trust company must have its
principal office in the United States and a combined capital and
surplus of at least $50 million. The depositary receipts
will evidence the depositary shares issued under the Deposit
Agreement.
The Deposit Agreement will contain terms applicable to the
holders of depositary shares in addition to the terms stated in
the depositary receipts. Each owner of depositary shares will be
entitled to all the rights and preferences of the preferred
stock underlying the depositary shares in proportion to the
applicable fractional interest in the underlying shares of
preferred stock. The depositary will issue the depositary
receipts to individuals purchasing the fractional interests in
shares of the related preferred stock according to the terms of
the offering described in a prospectus supplement.
Dividends
and Other Distributions
The depositary will distribute all cash dividends or other cash
distributions received for the preferred stock to the entitled
record holders of depositary shares in proportion to the number
of depositary shares that the holder owns on the relevant record
date. The depositary will distribute only an amount that can be
distributed without attributing to any holder of depositary
shares a fraction of one cent. The depositary will add the
undistributed balance to and treat it as part of the next sum
received by the depositary for distribution to holders of
depositary shares.
If there is a non-cash distribution, the depositary will
distribute property received by it to the entitled record
holders of depositary shares, in proportion, insofar as
possible, to the number of depositary shares owned by the
holders, unless the depositary determines, after consultation
with us, that it is not feasible to make such distribution. If
this occurs, the depositary may, with our approval, sell such
property and distribute the net proceeds from the sale to the
holders. The Deposit Agreement also will contain provisions
relating to
7
how any subscription or similar rights that we may offer to
holders of the preferred stock will be available to the holders
of the depositary shares.
Conversion,
Exchange and Redemption
If any series of preferred stock underlying the depositary
shares may be converted or exchanged, each record holder of
depositary receipts will have the right or obligation to convert
or exchange the depositary shares represented by the depositary
receipts.
Whenever we redeem shares of preferred stock held by the
depositary, the depositary will redeem, at the same time, the
number of depositary shares representing the preferred stock.
The depositary will redeem the depositary shares from the
proceeds it receives from the corresponding redemption, in whole
or in part, of the applicable series of preferred stock. The
depositary will mail notice of redemption to the record holders
of the depositary shares that are to be redeemed between 30 and
60 days before the date fixed for redemption. The
redemption price per depositary share will be equal to the
applicable fraction of the redemption price per share on the
applicable series of preferred stock. If less than all the
depositary shares are to be redeemed, the depositary will select
which shares to be redeemed by lot, proportionate allocation or
any other method.
After the date fixed for redemption, the depositary shares
called for redemption will no longer be outstanding. When the
depositary shares are no longer outstanding, all rights of the
holders will end, except the right to receive money, securities
or other property payable upon redemption.
Voting
When the depositary receives notice of a meeting at which the
holders of the preferred stock are entitled to vote, the
depositary will mail the particulars of the meeting to the
record holders of the depositary shares. Each record holder of
depositary shares on the record date may instruct the depositary
on how to vote the shares of preferred stock underlying the
holders depositary shares. The depositary will try, if
practical, to vote the number of shares of preferred stock
underlying the depositary shares according to the instructions.
The depositary will abstain from voting shares of the preferred
stock to the extent it does not receive specific instructions
from the holders of depositary shares representing such
preferred stock. We will agree to take all reasonable action
requested by the depositary to enable it to vote as instructed.
Record
Date
Whenever (1) any cash dividend or other cash distribution
shall become payable, any distribution other than cash shall be
made, or any rights, preferences or privileges shall be offered
with respect to the preferred stock, or (2) the depositary
shall receive notice of any meeting at which holders of
preferred stock are entitled to vote or of which holders of
preferred stock are entitled to notice, or of the mandatory
conversion of or any election on our part to call for the
redemption of any preferred stock, the depositary shall in each
such instance fix a record date (which shall be the same as the
record date for the preferred stock) for the determination of
the holders of depositary receipts (x) who shall be
entitled to receive such dividend, distribution, rights,
preferences or privileges or the net proceeds of the sale
thereof or (y) who shall be entitled to give instructions
for the exercise of voting rights at any such meeting or to
receive notice of such meeting or of such redemption or
conversion, subject to the provisions of the Deposit Agreement.
Amendments
We and the depositary may agree to amend the Deposit Agreement
and the depositary receipt evidencing the depositary shares. Any
amendment that (a) imposes or increases certain fees, taxes
or other charges payable by the holders of the depositary shares
as described in the Deposit Agreement or (b) otherwise
prejudices any substantial existing right of holders of
depositary shares, will not take effect until 30 days after
the depositary has mailed notice of the amendment to the record
holders of depositary shares. Any holder of depositary shares
that continues to hold its shares at the end of the
30-day
period will be deemed to have agreed to the amendment.
8
Termination
We may direct the depositary to terminate the Deposit Agreement
by mailing a notice of termination to holders of depositary
shares at least 30 days prior to termination. In addition,
a Deposit Agreement will automatically terminate if:
|
|
|
|
|
the depositary has redeemed all related outstanding depositary
shares, or
|
|
|
|
we have liquidated, terminated or wound up our business and the
depositary has distributed the preferred stock of the relevant
series to the holders of the related depositary shares.
|
The depositary may likewise terminate the Deposit Agreement if
at any time 60 days shall have expired after the depositary
shall have delivered to us a written notice of its election to
resign and a successor depositary shall not have been appointed
and accepted its appointment. If any depositary receipts remain
outstanding after the date of termination, the depositary
thereafter will discontinue the transfer of depositary receipts,
will suspend the distribution of dividends to the holders
thereof, and will not give any further notices (other than
notice of such termination) or perform any further acts under
the Deposit Agreement except as provided below and except that
the depositary will continue (1) to collect dividends on
the preferred stock and any other distributions with respect
thereto and (2) to deliver the preferred stock together
with such dividends and distributions and the net proceeds of
any sales of rights, preferences, privileges or other property,
without liability for interest thereon, in exchange for
depositary receipts surrendered. At any time after the
expiration of two years from the date of termination, the
depositary may sell the preferred stock then held by it at
public or private sales, at such place or places and upon such
terms as it deems proper and may thereafter hold the net
proceeds of any such sale, together with any money and other
property then held by it, without liability for interest
thereon, for the pro rata benefit of the holders of depositary
receipts which have not been surrendered.
Payment
of Fees and Expenses
We will pay all fees, charges and expenses of the depositary,
including the initial deposit of the preferred stock and any
redemption of the preferred stock. Holders of depositary shares
will pay transfer and other taxes and governmental charges and
any other charges as are stated in the Deposit Agreement for
their accounts.
Resignation
and Removal of Depositary
At any time, the depositary may resign by delivering notice to
us, and we may remove the depositary. Resignations or removals
will take effect upon the appointment of a successor depositary
and its acceptance of the appointment. The successor depositary
must be appointed within 60 days after delivery of the
notice of resignation or removal and must be a bank or trust
company having its principal office in the United States and
having a combined capital and surplus of at least
$50 million.
Reports
The depositary will forward to the holders of depositary shares
all reports and communications from us that are delivered to the
depositary and that we are required by law, the rules of an
applicable securities exchange or our amended and restated
certificate of incorporation to furnish to the holders of the
preferred stock. Neither we nor the depositary will be liable if
the depositary is prevented or delayed by law or any
circumstances beyond its control in performing its obligations
under the Deposit Agreement. The Deposit Agreement limits our
obligations and the depositarys obligations to performance
in good faith of the duties stated in the Deposit Agreement.
Neither we nor the depositary will be obligated to prosecute or
defend any legal proceeding connected with any depositary shares
or preferred stock unless the holders of depositary shares
requesting us to do so furnish us with satisfactory indemnity.
In performing our obligations, we and the depositary may rely
upon the written advice of our counsel or accountants, on any
information that competent people provide to us and on documents
that we believe are genuine.
9
DESCRIPTION
OF DEBT SECURITIES
The following descriptions of the debt securities do not purport
to be complete and are subject to and qualified in their
entirety by reference to the indenture, which has been filed
with the SEC as an exhibit to the registration statement of
which this prospectus forms a part. Any future supplemental
indenture or similar document also will be so filed. You should
read the indenture and any supplemental indenture or similar
document because they, and not this description, define your
rights as holder of our debt securities. All capitalized terms
have the meanings specified in the indenture.
We may issue, from time to time, debt securities, in one or more
series, that will consist of either our senior debt
(Senior Debt Securities), our senior subordinated
debt (Senior Subordinated Debt Securities), our
subordinated debt (Subordinated Debt Securities) or
our junior subordinated debt (Junior Subordinated Debt
Securities and, together with the Senior Subordinated Debt
Securities and the Subordinated Debt Securities, the
Subordinated Securities). The debt securities we
offer will be issued under an indenture between us and The Bank
of New York Mellon Trust Company, N.A. (formerly known as
the Bank of New York Trust Company, N.A.), acting as
trustee. Debt securities, whether senior, senior subordinated,
subordinated or junior subordinated, may be issued as
convertible debt securities or exchangeable debt securities.
General
Terms of the Indenture
The indenture does not limit the amount of debt securities that
we may issue. It provides that we may issue debt securities up
to the principal amount that we may authorize and may be in any
currency or currency unit designated by us. Except for the
limitations on consolidation, merger and sale of all or
substantially all of our assets contained in the indenture, the
terms of the indenture do not contain any covenants or other
provisions designed to afford holders of any debt securities
protection with respect to our operations, financial condition
or transactions involving us.
We may issue the debt securities issued under the indenture as
discount securities, which means they may be sold at
a discount below their stated principal amount. These debt
securities, as well as other debt securities that are not issued
at a discount, may, for U.S. federal income tax purposes,
be treated as if they were issued with original issue
discount, or OID, because of interest payment
and other characteristics. Special U.S. federal income tax
considerations applicable to debt securities issued with
original issue discount will be described in more detail in any
applicable prospectus supplement.
The applicable prospectus supplement for a series of debt
securities that we issue will describe, among other things, the
following terms of the offered debt securities:
|
|
|
|
|
the title;
|
|
|
|
the aggregate principal amount;
|
|
|
|
whether issued in fully registered form without coupons or in a
form registered as to principal only with coupons or in bearer
form with coupons;
|
|
|
|
whether issued in the form of one or more global securities and
whether all or a portion of the principal amount of the debt
securities is represented thereby;
|
|
|
|
the price or prices at which the debt securities will be issued;
|
|
|
|
the date or dates on which principal is payable;
|
|
|
|
the place or places where and the manner in which principal,
premium or interest will be payable and the place or places
where the debt securities may be presented for transfer and, if
applicable, conversion or exchange;
|
|
|
|
interest rates, and the dates from which interest, if any, will
accrue, and the dates when interest is payable;
|
|
|
|
the right, if any, to extend the interest payment periods and
the duration of the extensions;
|
10
|
|
|
|
|
our rights or obligations to redeem or purchase the debt
securities, including sinking fund or partial redemption
payments;
|
|
|
|
conversion or exchange provisions, if any, including conversion
or exchange prices or rates and adjustments thereto;
|
|
|
|
the currency or currencies of payment of principal or interest;
|
|
|
|
the terms applicable to any debt securities issued at a discount
from their stated principal amount;
|
|
|
|
the terms, if any, pursuant to which any debt securities will be
subordinate to any of our other debt;
|
|
|
|
if the amount of payments of principal or interest is to be
determined by reference to an index or formula, or based on a
coin or currency other than that in which the debt securities
are stated to be payable, the manner in which these amounts are
determined and the calculation agent, if any, with respect
thereto;
|
|
|
|
if other than the entire principal amount of the debt securities
when issued, the portion of the principal amount payable upon
acceleration of maturity as a result of a default on our
obligations;
|
|
|
|
any provisions for the remarketing of the debt securities;
|
|
|
|
if applicable, covenants affording holders of debt protection
with respect to our operations, financial condition or
transactions involving us; and
|
|
|
|
any other specific terms of any debt securities.
|
The applicable prospectus supplement will set forth certain
U.S. federal income tax considerations for holders of any
debt securities and the securities exchange or quotation system
on which any debt securities are listed or quoted, if any.
Debt securities issued by us will be structurally subordinated
to all indebtedness and other liabilities of our subsidiaries,
except to the extent any such subsidiary guarantees or is
otherwise obligated to make payment on such debt securities.
Unless otherwise provided in the applicable prospectus
supplement, all securities of any one series need not be issued
at the same time and may be issued from time to time without
consent of any holder.
Senior
Debt Securities
Payment of the principal of, and premium, if any, and interest
on, Senior Debt Securities will rank on a parity with all of our
other unsecured and unsubordinated debt.
Senior
Subordinated Debt Securities
Payment of the principal of, and premium, if any, and interest
on, Senior Subordinated Debt Securities will be junior in right
of payment to the prior payment in full of all of our
unsubordinated debt. We will set forth in the applicable
prospectus supplement relating to any Senior Subordinated Debt
Securities the subordination terms of such securities as well as
the aggregate amount of outstanding debt, as of the most recent
practicable date, that by its terms would be senior to the
Senior Subordinated Debt Securities. We will also set forth in
such prospectus supplement limitations, if any, on issuance of
additional senior debt.
Subordinated
Debt Securities
Payment of the principal of, and premium, if any, and interest
on, Subordinated Debt Securities will be subordinated and junior
in right of payment to the prior payment in full of all of our
unsubordinated and senior subordinated debt. We will set forth
in the applicable prospectus supplement relating to any
Subordinated Debt Securities the subordination terms of such
securities as well as the aggregate amount of outstanding
indebtedness, as of the most recent practicable date, that by
its terms would be senior to the
11
Subordinated Debt Securities. We will also set forth in such
prospectus supplement limitations, if any, on issuance of
additional senior debt.
Junior
Subordinated Debt Securities
Payment of the principal of, and premium, if any, and interest
on, Junior Subordinated Debt Securities will be subordinated and
junior in right of payment to the prior payment in full of all
of our subordinated, senior subordinated and subordinated debt.
We will set forth in the applicable prospectus supplement
relating to any Junior Subordinated Debt Securities the
subordination terms of such securities as well as the aggregate
amount of outstanding debt, as of the most recent practicable
date, that by its terms would be senior to the Junior
Subordinated Debt Securities. We will also set forth in such
prospectus supplement limitations, if any, on issuance of
additional senior debt.
Conversion
or Exchange Rights
Debt securities may be convertible into or exchangeable for
other securities or property of McKesson. The terms and
conditions of conversion or exchange will be set forth in the
applicable prospectus supplement. The terms will include, among
others, the following:
|
|
|
|
|
the conversion or exchange price;
|
|
|
|
the conversion or exchange period;
|
|
|
|
provisions regarding the ability of us or the holder to convert
or exchange the debt securities;
|
|
|
|
events requiring adjustment to the conversion or exchange
price; and
|
|
|
|
provisions affecting conversion or exchange in the event of our
redemption of the debt securities.
|
Consolidation,
Merger or Sale
We cannot consolidate or merge with or into, or transfer or
lease all or substantially all of our assets to, any person
unless (a) we will be the continuing corporation or
(b) the successor corporation or person to which our assets
are transferred or leased is a corporation organized under the
laws of the United States, any state of the United States or the
District of Columbia and it expressly assumes our obligations on
the debt securities and under the indenture. In addition, we
cannot effect such a transaction unless immediately after giving
effect to such transaction, no default or event of default under
the indenture shall have occurred and be continuing. Subject to
certain exceptions, when the person to whom our assets are
transferred or leased has assumed our obligations under the debt
securities and the indenture, we shall be discharged from all
our obligations under the debt securities and the indenture,
except in limited circumstances.
This covenant would not apply to any recapitalization
transaction, a change of control of McKesson or a highly
leveraged transaction, unless the transaction or change of
control were structured to include a merger or consolidation or
transfer or lease of all or substantially all of our assets.
Events of
Default
Unless otherwise indicated, the term Event of
Default, when used in the indenture with respect to the
debt securities of any series means any of the following:
|
|
|
|
|
failure to pay interest for 30 days after the date payment
on any debt security of such series is due and payable; provided
that an extension of an interest payment period by McKesson in
accordance with the terms of the debt securities shall not
constitute a failure to pay interest;
|
|
|
|
failure to pay principal or premium, if any, on any debt
security of such series when due, either at maturity, upon any
redemption, by declaration or otherwise;
|
|
|
|
failure to make sinking fund payments when due;
|
12
|
|
|
|
|
failure to perform any other covenant in the indenture or the
debt securities of such series (other covenants) for
90 days after notice that performance was required;
|
|
|
|
events in bankruptcy, insolvency or reorganization of
McKesson; or
|
|
|
|
any other Event of Default provided in the applicable resolution
of our board of directors or the officers certificate or
supplemental indenture under which we issue such series of debt
securities.
|
An Event of Default for a particular series of debt securities
does not necessarily constitute an Event of Default for any
other series of debt securities issued under the indenture. If
an Event of Default relating to the payment of interest,
principal or any sinking fund installment involving any series
of debt securities has occurred and is continuing, the trustee
or the holders of not less than 25% in aggregate principal
amount of the debt securities of each affected series may
declare the entire principal of all the debt securities of that
series to be due and payable immediately.
If an Event of Default relating to the performance of other
covenants occurs and is continuing for a period of 90 days
after notice of such, or if any other Event of Default occurs
and is continuing involving all of the series of Senior Debt
Securities, then the trustee or the holders of not less than 25%
in aggregate principal amount of all of the series of Senior
Debt Securities may declare the entire principal amount of all
of the series of Senior Debt Securities due and payable
immediately.
Similarly, if an Event of Default relating to the performance of
other covenants occurs and is continuing for a period of
90 days after notice of such, or if any other Event of
Default occurs and is continuing involving all of the series of
Subordinated Securities, then the trustee or the holders of not
less than 25% in aggregate principal amount of all of the series
of Subordinated Securities may declare the entire principal
amount of all of the series of Subordinated Securities due and
payable immediately.
If, however, the Event of Default relating to the performance of
other covenants or any other Event of Default that has occurred
and is continuing is for less than all of the series of Senior
Debt Securities or Subordinated Securities, as the case may be,
then, the trustee or the holders of not less than 25% in
aggregate principal amount of each affected series of the Senior
Debt Securities or the Subordinated Securities, as the case may
be, may declare the entire principal amount of all debt
securities of such affected series due and payable immediately.
The holders of not less than a majority in aggregate principal
amount of the debt securities of a series may, after satisfying
conditions, rescind and annul any of the above-described
declarations and consequences involving the series.
If an Event of Default relating to events in bankruptcy,
insolvency or reorganization of McKesson occurs and is
continuing, then the principal amount of all of the debt
securities outstanding, and any accrued interest, will
automatically become due and payable immediately, without any
declaration or other act by the trustee or any holder.
The indenture imposes limitations on suits brought by holders of
debt securities against us. Except as provided below, no holder
of debt securities of any series may institute any action
against us under the indenture unless:
|
|
|
|
|
the holder has previously given to the trustee written notice of
default and continuance of that default,
|
|
|
|
the holders of at least 25% in principal amount of the
outstanding debt securities of the affected series have
requested that the trustee institute the action,
|
|
|
|
the requesting holders have offered the trustee reasonable
security or indemnity satisfactory to it for expenses and
liabilities that may be incurred by bringing the action,
|
|
|
|
the trustee has not instituted the action within 60 days of
the request, and
|
|
|
|
the trustee has not received inconsistent direction by the
holders of a majority in principal amount of the outstanding
debt securities of the affected series.
|
Notwithstanding the foregoing, each holder of debt securities of
any series has the right, which is absolute and unconditional,
to receive payment of the principal of, and premium and
interest, if any, on, such
13
debt securities when due and to institute suit for the
enforcement of any such payment, and such rights may not be
impaired without the consent of that holder of debt securities.
We will be required to file annually with the Trustee a
certificate, signed by an officer of McKesson, stating whether
or not the officer knows of any default by us in the
performance, observance or fulfillment of any condition or
covenant of the indenture.
Registered
Global Securities
We may issue the debt securities of a series in whole or in part
in the form of one or more fully registered global securities
that we will deposit with a depositary or with a nominee for a
depositary identified in the applicable prospectus supplement
and registered in the name of such depositary or nominee. In
such case, we will issue one or more registered global
securities denominated in an amount equal to the aggregate
principal amount of all of the debt securities of the series to
be issued and represented by such registered global security or
securities.
Unless and until it is exchanged in whole or in part for debt
securities in definitive registered form, a registered global
security may not be transferred except as a whole:
|
|
|
|
|
by the depositary for such registered global security to its
nominee,
|
|
|
|
by a nominee of the depositary to the depositary or another
nominee of the depositary, or
|
|
|
|
by the depositary or its nominee to a successor of the
depositary or a nominee of the successor.
|
The prospectus supplement relating to a series of debt
securities will describe the specific terms of the depositary
arrangement with respect to any portion of such series
represented by a registered global security. We anticipate that
the following provisions will apply to all depositary
arrangements for debt securities:
|
|
|
|
|
ownership of beneficial interests in a registered global
security will be limited to persons that have accounts with the
depositary for the registered global security, those persons
being referred to as participants, or persons that
may hold interests through participants;
|
|
|
|
upon the issuance of a registered global security, the
depositary for the registered global security will credit, on
its book-entry registration and transfer system, the
participants accounts with the respective principal
amounts of the debt securities represented by the registered
global security beneficially owned by the participants;
|
|
|
|
any dealers, underwriters, or agents participating in the
distribution of the debt securities will designate the accounts
to be credited; and
|
|
|
|
ownership of any beneficial interest in the registered global
security will be shown on, and the transfer of any ownership
interest will be effected only through, records maintained by
the depositary for the registered global security (with respect
to interests of participants) and on the records of participants
(with respect to interests of persons holding through
participants).
|
The laws of some states may require that certain purchasers of
securities take physical delivery of the securities in
definitive form. These laws may limit the ability of those
persons to own, transfer or pledge beneficial interests in
registered global securities.
So long as the depositary for a registered global security, or
its nominee, is the registered owner of the registered global
security, the depositary or the nominee, as the case may be,
will be considered the sole owner or holder of the debt
securities represented by the registered global security for all
purposes under the indenture. Except as set forth below, owners
of beneficial interests in a registered global security:
|
|
|
|
|
will not be entitled to have the debt securities represented by
a registered global security registered in their names,
|
14
|
|
|
|
|
will not receive or be entitled to receive physical delivery of
the debt securities in the definitive form and
|
|
|
|
will not be considered the owners or holders of the debt
securities under the indenture.
|
Accordingly, each person owning a beneficial interest in a
registered global security must rely on the procedures of the
depositary for the registered global security and, if the person
is not a participant, on the procedures of a participant through
which the person owns its interest, to exercise any rights of a
holder under the indenture.
We understand that under existing industry practices, if we
request any action of holders or if an owner of a beneficial
interest in a registered global security desires to give or take
any action that a holder is entitled to give or take under the
indenture, the depositary for the registered global security
would authorize the participants holding the relevant beneficial
interests to give or take the action, and those participants
would authorize beneficial owners owning through those
participants to give or take the action or would otherwise act
upon the instructions of beneficial owners holding through them.
We will make payments of principal and premium, if any, and
interest, if any, on debt securities represented by a registered
global security registered in the name of a depositary or its
nominee to the depositary or its nominee, as the case may be, as
the registered owners of the registered global security. None of
McKesson, the trustee or any other agent of McKesson or the
trustee will be responsible or liable for any aspect of the
records relating to, or payments made on account of, beneficial
ownership interests in the registered global security or for
maintaining, supervising or reviewing any records relating to
the beneficial ownership interests.
We expect that the depositary for any debt securities
represented by a registered global security, upon receipt of any
payments of principal and premium, if any, and interest, if any,
in respect of the registered global security, will immediately
credit participants accounts with payments in amounts
proportionate to their respective beneficial interests in the
registered global security as shown on the records of the
depositary. We also expect that standing customer instructions
and customary practices will govern payments by participants to
owners of beneficial interests in the registered global security
held through the participants, as is now the case with the
securities held for the accounts of customers in bearer form or
registered in street name. We also expect that any
of these payments will be the responsibility of the participants.
If the depositary for any debt securities represented by a
registered global security is at any time unwilling or unable to
continue as depositary or ceases to be a clearing agency
registered under the Exchange Act, we will appoint an eligible
successor depositary. If we fail to appoint an eligible
successor depositary within 90 days, we will issue the debt
securities in definitive form in exchange for the registered
global security. In addition, we may at any time and in our sole
discretion decide not to have any of the debt securities of a
series represented by one or more registered global securities.
In such event, we will issue debt securities of that series in a
definitive form in exchange for all of the registered global
securities representing the debt securities. The trustee will
register any debt securities issued in definitive form in
exchange for a registered global security in such name or names
as the depositary, based upon instructions from its
participants, shall instruct the trustee.
We may also issue bearer debt securities of a series in the form
of one or more global securities, referred to as bearer
global securities. We will deposit these bearer global
securities with a common depositary for Euroclear Bank S.A./N.V.
and Clearstream Banking, société anonyme, or
with a nominee for the depositary identified in the prospectus
supplement relating to that series. The prospectus supplement
relating to a series of debt securities represented by a bearer
global security will describe the specific terms and procedures,
including the specific terms of the depositary arrangement and
any specific procedures for the issuance of debt securities in
definitive form in exchange for a bearer global security, with
respect to the portion of the series represented by a bearer
global security.
15
Discharge,
Defeasance and Covenant Defeasance
We can discharge or defease our obligations under the indenture
as set forth below. Unless otherwise set forth in the applicable
prospectus supplement, the subordination provisions applicable
to any Subordinated Securities will be expressly made subject to
the discharge and defeasance provisions of the indenture.
We may discharge our obligations to holders of any series of
debt securities that have not already been delivered to the
trustee for cancellation and that have either become due and
payable or are by their terms to become due and payable within
one year (or are scheduled for redemption within one year). We
may effect a discharge by irrevocably depositing with the
trustee cash or U.S. government obligations, as trust
funds, in an amount certified to be sufficient to pay when due,
whether at maturity, upon redemption or otherwise, the principal
of, and premium, if any, and interest on, the debt securities
and any mandatory sinking fund payments.
Unless otherwise provided in the applicable prospectus
supplement, we may also discharge any and all of our obligations
to holders of any series of debt securities at any time
(legal defeasance). We also may be released from the
obligations imposed by any covenants of any outstanding series
of debt securities and provisions of the indenture, and we may
omit to comply with those covenants without creating an Event of
Default (covenant defeasance). We may effect legal
defeasance and covenant defeasance only if, among other things:
|
|
|
|
|
we irrevocably deposit with the trustee cash or
U.S. government obligations, as trust funds, in an amount
certified to be sufficient to pay when due (whether at maturity,
upon redemption, or otherwise) the principal of, and premium, if
any, and interest on all outstanding debt securities of the
series; and
|
|
|
|
we deliver to the trustee an opinion of counsel from a
nationally recognized law firm to the effect that the holders of
the series of debt securities will not recognize income, gain or
loss for U.S. federal income tax purposes as a result of
the legal defeasance or covenant defeasance and that legal
defeasance or covenant defeasance will not otherwise alter the
holders U.S. federal income tax treatment of
principal, premium, if any, and interest payments on the series
of debt securities, which opinion, in the case of legal
defeasance, must be based on a ruling of the Internal Revenue
Service, or a change in U.S. federal income tax law.
|
Although we may discharge or defease our obligations under the
indenture as described in the two preceding paragraphs, we may
not avoid, among other things, our duty to register the transfer
or exchange of any series of debt securities, to replace any
temporary, mutilated, destroyed, lost or stolen series of debt
securities or to maintain an office or agency in respect of any
series of debt securities.
Modification
of the Indenture
The indenture provides that we and the trustee may enter into
supplemental indentures without the consent of the holders of
debt securities to:
|
|
|
|
|
secure any debt securities,
|
|
|
|
evidence the assumption by a successor corporation of our
obligations,
|
|
|
|
add covenants for the protection of the holders of debt
securities,
|
|
|
|
cure any ambiguity or correct any inconsistency in the indenture,
|
|
|
|
establish the forms or terms of debt securities of any
series and
|
|
|
|
evidence and provide for the acceptance of appointment by a
successor trustee.
|
The indenture also provides that we and the trustee may, with
the consent of the holders of not less than a majority in
aggregate principal amount of debt securities of all series of
Senior Debt Securities or Subordinated Securities, as the case
may be, then outstanding and affected thereby (voting as one
class), add any provisions to, or change in any manner,
eliminate or modify in any way the provisions of, the indenture
or
16
modify in any manner the rights of the holders of the debt
securities. We and the trustee may not, however, without the
consent of the holder of each outstanding debt security affected
thereby:
|
|
|
|
|
extend the final maturity of any debt security;
|
|
|
|
reduce the principal amount or premium, if any;
|
|
|
|
reduce the rate or extend the time of payment of interest;
|
|
|
|
reduce any amount payable on redemption;
|
|
|
|
change the currency in which the principal (other than as may be
provided otherwise with respect to a series), premium, if any,
or interest is payable;
|
|
|
|
reduce the amount of the principal of any debt security issued
with an original issue discount that is payable upon
acceleration or provable in bankruptcy;
|
|
|
|
modify any of the subordination provisions or the definition of
senior indebtedness applicable to any Subordinated Securities in
a manner adverse to the holders of those securities;
|
|
|
|
alter provisions of the indenture relating to the debt
securities not denominated in U.S. dollars;
|
|
|
|
impair the right to institute suit for the enforcement of any
payment on any debt security when due; or
|
|
|
|
reduce the percentage of holders of debt securities of any
series whose consent is required for any modification of the
indenture.
|
Concerning
the Trustee
The indenture provides that there may be more than one trustee
under the indenture, each with respect to one or more series of
debt securities. If there are different trustees for different
series of debt securities, each trustee will be a trustee of a
trust under the indenture separate and apart from the trust
administered by any other trustee under the indenture. Except as
otherwise indicated in this prospectus or any prospectus
supplement, any action permitted to be taken by a trustee may be
taken by such trustee only with respect to the one or more
series of debt securities for which it is the trustee under the
indenture. Any trustee under the indenture may resign or be
removed with respect to one or more series of debt securities.
All payments of principal of, and premium, if any, and interest
on, and all registration, transfer, exchange, authentication and
delivery (including authentication and delivery on original
issuance of the debt securities) of, the debt securities of a
series will be effected by the trustee with respect to that
series at an office designated by the trustee in New York, New
York.
The indenture contains limitations on the right of the trustee,
should it become a creditor of McKesson, to obtain payment of
claims in some cases or to realize on certain property received
in respect of any such claim as security or otherwise. The
trustee may engage in other transactions. If it acquires any
conflicting interest relating to any duties with respect to the
debt securities, however, it must eliminate the conflict or
resign as trustee.
The holders of a majority in aggregate principal amount of any
series of debt securities then outstanding will have the right
to direct the time, method and place of conducting any
proceeding for exercising any remedy available to the trustee
with respect to such series of debt securities, provided that
the direction would not conflict with any rule of law or with
the indenture, would not be unduly prejudicial to the rights of
another holder of the debt securities, and would not involve any
trustee in personal liability. The indenture provides that in
case an Event of Default shall occur and be known to any trustee
and not be cured, the trustee must use the same degree of care
as a prudent person would use in the conduct of his or her own
affairs in the exercise of the trustees power. Subject to
these provisions, the trustee will be under no obligation to
exercise any of its rights or powers under the indenture at the
request of any of the holders of the debt securities, unless
they shall have offered to the trustee security and indemnity
satisfactory to the trustee.
17
No
Individual Liability of Incorporators, Stockholders, Officers or
Directors
The indenture provides that no incorporator and no past, present
or future stockholder, officer or director, of McKesson or any
successor corporation in their capacity as such shall have any
individual liability for any of our obligations, covenants or
agreements under the debt securities or the indenture.
Governing
Law
The indenture and the debt securities will be governed by, and
construed in accordance with, the laws of the State of New York,
including, without limitation,
Sections 5-1401
and 5-1402 of the New York General Obligations Law and New York
Civil Practice Law and Rules 327(b).
DESCRIPTION
OF WARRANTS
General
We may issue debt warrants for the purchase of debt securities
or stock warrants for the purchase of preferred stock or common
stock.
The warrants will be issued under warrant agreements to be
entered into between us and a bank or trust company, as warrant
agent, all to be set forth in the applicable prospectus
supplement relating to any or all warrants in respect of which
this prospectus is being delivered. Copies of the form of
agreement for each warrant, including the forms of certificates
representing the warrants reflecting the provisions to be
included in such agreements that will be entered into with
respect to the particular offerings of each type of warrant are
filed as exhibits to the registration statement of which this
prospectus forms a part.
The following description sets forth certain general terms and
provisions of the warrants to which any prospectus supplement
may relate. The particular terms of the warrants to which any
prospectus supplement may relate and the extent, if any, to
which such general provisions may apply to the warrants so
offered will be described in the applicable prospectus
supplement. The following summary of certain provisions of the
warrants, warrant agreements and warrant certificates does not
purport to be complete and is subject to, and is qualified in
its entirety by express reference to, all the provisions of the
warrant agreements and warrant certificates, including the
definitions therein of certain terms.
Debt
Warrants
General. Reference is made to the applicable
prospectus supplement for the terms of debt warrants in respect
of which this prospectus is being delivered, the debt securities
warrant agreement relating to such debt warrants and the debt
warrant certificates representing such debt warrants, including
the following:
|
|
|
|
|
the designation, aggregate principal amount and terms of the
debt securities purchasable upon exercise of such debt warrants
and the procedures and conditions relating to the exercise of
such debt warrants;
|
|
|
|
the designation and terms of any related debt securities with
which such debt warrants are issued and the number of such debt
warrants issued with each such debt security;
|
|
|
|
the date, if any, on and after which such debt warrants and any
related offered securities will be separately transferable;
|
|
|
|
the principal amount of debt securities purchasable upon
exercise of each debt warrant and the price at which such
principal amount of debt securities may be purchased upon such
exercise;
|
|
|
|
the date on which the right to exercise such debt warrants shall
commence and the date on which such right shall expire;
|
|
|
|
a discussion of the material United States federal income tax
considerations applicable to the ownership or exercise of debt
warrants;
|
18
|
|
|
|
|
whether the debt warrants represented by the debt warrant
certificates will be issued in registered or bearer form, and,
if registered, where they may be transferred and registered;
|
|
|
|
call provisions of such debt warrants, if any; and
|
|
|
|
any other terms of the debt warrants.
|
The debt warrant certificates will be exchangeable for new debt
warrant certificates of different denominations and debt
warrants may be exercised at the corporate trust office of the
warrant agent or any other office indicated in the applicable
prospectus supplement. Prior to the exercise of their debt
warrants, holders of debt warrants will not have any of the
rights of holders of the debt securities purchasable upon such
exercise and will not be entitled to any payments of principal
and premium, if any, and interest, if any, on the debt
securities purchasable upon such exercise.
Exercise of Debt Warrants. Each debt warrant
will entitle the holder to purchase for cash such principal
amount of debt securities at such exercise price as shall in
each case be set forth in, or be determinable as set forth in,
the applicable prospectus supplement relating to the debt
warrants offered thereby. Unless otherwise specified in the
applicable prospectus supplement, debt warrants may be exercised
at any time up to 5:00 p.m., New York City time, on the
expiration date set forth in the applicable prospectus
supplement. After 5:00 p.m., New York City time, on the
expiration date, unexercised debt warrants will become void.
Debt warrants may be exercised as set forth in the applicable
prospectus supplement relating to the debt warrants. Upon
receipt of payment and the debt warrant certificate properly
completed and duly executed at the corporate trust office of the
warrant agent or any other office indicated in the applicable
prospectus supplement, we will, as soon as practicable, forward
the debt securities purchasable upon such exercise. If less than
all of the debt warrants represented by such debt warrant
certificate are exercised, a new debt warrant certificate will
be issued for the remaining amount of debt warrants.
Stock
Warrants
General. Reference is made to the applicable
prospectus supplement for the terms of stock warrants in respect
of which this prospectus is being delivered, the stock warrant
agreement relating to such stock warrants and the stock warrant
certificates representing such stock warrants, including the
following:
|
|
|
|
|
the type and number of shares of preferred stock or common stock
purchasable upon exercise of such stock warrants and the
procedures and conditions relating to the exercise of such stock
warrants;
|
|
|
|
the date, if any, on and after which such stock warrants and
related offered securities will be separately tradeable;
|
|
|
|
the offering price of such stock warrants, if any;
|
|
|
|
the initial price at which such shares may be purchased upon
exercise of stock warrants and any provision with respect to the
adjustment thereof;
|
|
|
|
the date on which the right to exercise such stock warrants
shall commence and the date on which such right shall expire;
|
|
|
|
a discussion of the material United States federal income tax
considerations applicable to the ownership or exercise of stock
warrants;
|
|
|
|
call provisions of such stock warrants, if any;
|
|
|
|
any other terms of the stock warrants;
|
|
|
|
anti-dilution provisions of the stock warrants, if any; and
|
|
|
|
information relating to any preferred stock purchasable upon
exercise of such stock warrants.
|
The stock warrant certificates will be exchangeable for new
stock warrant certificates of different denominations and stock
warrants may be exercised at the corporate trust office of the
warrant agent or any
19
other office indicated in the applicable prospectus supplement.
Prior to the exercise of their stock warrants, holders of stock
warrants will not have any of the rights of holders of shares of
capital stock purchasable upon such exercise, and will not be
entitled to any dividend payments on such capital stock
purchasable upon such exercise.
Exercise of Stock Warrants. Each stock warrant
will entitle the holder to purchase for cash such number of
shares of preferred stock or common stock, as the case may be,
at such exercise price as shall in each case be set forth in, or
be determinable as set forth in, the applicable prospectus
supplement relating to the stock warrants offered thereby.
Unless otherwise specified in the applicable prospectus
supplement, stock warrants may be exercised at any time up to
5:00 p.m., New York City time, on the expiration date set
forth in the applicable prospectus supplement. After
5:00 p.m., New York City time, on the expiration date,
unexercised stock warrants will become void.
Stock warrants may be exercised as set forth in the applicable
prospectus supplement relating thereto. Upon receipt of payment
and the stock warrant certificates properly completed and duly
executed at the corporate trust office of the warrant agent or
any other office indicated in the applicable prospectus
supplement, we will, as soon as practicable, forward a
certificate representing the number of shares of capital stock
purchasable upon such exercise. If less than all of the stock
warrants represented by such stock warrant certificate are
exercised, a new stock warrant certificate will be issued for
the remaining amount of stock warrants.
DESCRIPTION
OF STOCK PURCHASE CONTRACTS AND STOCK PURCHASE UNITS
We may issue stock purchase contracts, representing contracts
obligating holders to purchase from us, and requiring us to sell
to the holders, a specified number of shares of common stock at
a future date or dates. The price per share of common stock may
be fixed at the time the stock purchase contracts are issued or
may be determined by reference to a specific formula set forth
in the stock purchase contracts. The stock purchase contracts
may be issued separately or as a part of units, or stock
purchase units, consisting of a stock purchase contract and
either (x) senior debt securities, senior subordinated debt
securities, subordinated debt securities or junior subordinated
debt securities, or (y) debt obligations of third parties,
including U.S. Treasury securities, in each case, securing
the holders obligations to purchase the common stock under
the stock purchase contracts. The stock purchase contracts may
require us to make periodic payments to the holders of the stock
purchase contracts or vice versa, and such payments may be
unsecured or prefunded on some basis. The stock purchase
contracts may require holders to secure their obligations
thereunder in a specified manner and in certain circumstances we
may deliver newly issued prepaid stock purchase contracts, or
prepaid securities, upon release to a holder of any collateral
securing such holders obligations under the original stock
purchase contract.
The applicable prospectus supplement will describe the terms of
any stock purchase contracts or stock purchase units and, if
applicable, prepaid securities. The description in the
prospectus supplement will not purport to be complete and will
be qualified in its entirety by reference to the stock purchase
contracts, the collateral arrangements and depositary
arrangements, if applicable, relating to such stock purchase
contracts or stock purchase units and, if applicable, the
prepaid securities and the document pursuant to which such
prepaid securities will be issued.
PLAN OF
DISTRIBUTION
McKesson may sell common stock, preferred stock, depositary
shares, debt securities, warrants, stock purchase contracts or
stock purchase units in one or more of the following ways from
time to time:
|
|
|
|
|
to or through underwriters or dealers;
|
|
|
|
by itself directly;
|
20
|
|
|
|
|
through agents; or
|
|
|
|
through a combination of any of these methods of sale.
|
The prospectus supplements relating to an offering of offered
securities will set forth the terms of such offering, including:
|
|
|
|
|
the name or names of any underwriters, dealers or agents;
|
|
|
|
the purchase price of the offered securities and the proceeds to
McKesson from the sale;
|
|
|
|
any underwriting discounts and commissions or agency fees and
other items constituting underwriters or agents
compensation; and
|
|
|
|
any initial public offering price, any discounts or concessions
allowed or reallowed or paid to dealers and any securities
exchanges on which such offered securities may be listed.
|
Any initial public offering prices, discounts or concessions
allowed or reallowed or paid to dealers may be changed from time
to time.
If underwriters are used in the sale, the underwriters will
acquire the offered securities for their own account and may
resell them from time to time in one or more transactions,
including negotiated transactions, at a fixed public offering
price or at varying prices determined at the time of sale. The
offered securities may be offered either to the public through
underwriting syndicates represented by one or more managing
underwriters or by one or more underwriters without a syndicate.
Unless otherwise set forth in a prospectus supplement, the
obligations of the underwriters to purchase any series of
securities will be subject to certain conditions precedent, and
the underwriters will be obligated to purchase all of such
series of securities if any are purchased.
In connection with underwritten offerings of the offered
securities and in accordance with applicable law and industry
practice, underwriters may over-allot or effect transactions
that stabilize, maintain or otherwise affect the market price of
the offered securities at levels above those that might
otherwise prevail in the open market, including by entering
stabilizing bids, effecting syndicate covering transactions or
imposing penalty bids, each of which is described below.
|
|
|
|
|
A stabilizing bid means the placing of any bid, or the effecting
of any purchase, for the purpose of pegging, fixing or
maintaining the price of a security.
|
|
|
|
A syndicate covering transaction means the placing of any bid on
behalf of the underwriting syndicate or the effecting of any
purchase to reduce a short position created in connection with
the offering.
|
|
|
|
A penalty bid means an arrangement that permits the managing
underwriter to reclaim a selling concession from a syndicate
member in connection with the offering when offered securities
originally sold by the syndicate member are purchased in
syndicate covering transactions.
|
These transactions may be effected on the NYSE, in the
over-the-counter market, or otherwise. Underwriters are not
required to engage in any of these activities, or to continue
such activities if commenced.
If a dealer is used in the sale, McKesson will sell such offered
securities to the dealer, as principal. The dealer may then
resell the offered securities to the public at varying prices to
be determined by that dealer at the time for resale. The names
of the dealers and the terms of the transaction will be set
forth in the prospectus supplement relating to that transaction.
Offered securities may be sold directly by McKesson to one or
more institutional purchasers, or through agents designated by
McKesson from time to time, at a fixed price or prices, which
may be changed, or at varying prices determined at the time of
sale. Any agent involved in the offer or sale of the offered
securities in respect of which this prospectus is delivered will
be named, and any commissions payable by McKesson to such agent
will be set forth, in the prospectus supplement relating to that
offering. Unless otherwise indicated in such prospectus
supplement, any such agent will be acting on a best efforts
basis for the period of its appointment.
21
Underwriters, dealers and agents may be entitled under
agreements entered into with us to indemnification by us against
certain civil liabilities, including liabilities under the
Securities Act, or to contribution with respect to payments that
the underwriters, dealers or agents may be required to make in
respect thereof. Underwriters, dealers and agents may be
customers of, engage in transactions with, or perform services
for us and our affiliates in the ordinary course of business.
Other than our common stock, which is listed on the New York
Stock Exchange, each of the securities issued hereunder will be
a new issue of securities, will have no prior trading market,
and may or may not be listed on a national securities exchange.
Any common stock sold pursuant to a prospectus supplement will
be listed on the New York Stock Exchange, subject to official
notice of issuance. Any underwriters to whom McKesson sells
securities for public offering and sale may make a market in the
securities, but such underwriters will not be obligated to do so
and may discontinue any market making at any time without
notice. We cannot assure you that there will be a market for the
offered securities.
LEGAL
MATTERS
The validity of the securities being offered hereby is being
passed upon for McKesson Corporation by Skadden, Arps, Slate,
Meagher & Flom LLP, Los Angeles, California.
EXPERTS
The consolidated financial statements, the related financial
statement schedule, incorporated in this prospectus by reference
from McKesson Corporations Annual Report on
Form 10-K
for the fiscal year ended March 31, 2008, and the
effectiveness of the Companys internal control over
financial reporting have been audited by Deloitte &
Touche LLP, an independent registered public accounting firm, as
stated in their report, which is incorporated herein by
reference. Such financial statements and financial statement
schedule have been so incorporated in reliance upon the report
of such firm given upon their authority as experts in accounting
and auditing.
22
$
McKesson Corporation
$ % Notes
due 2016
$ % Notes
due 2021
$ % Notes
due 2041
Prospectus Supplement
February ,
2011
BofA Merrill Lynch
J.P. Morgan